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CHAPTER I
AN INTRODUCTION TO MELANOMA AND MELANOMA THERAPY
Melanoma predisposition
Melanoma, the malignant tumor of melanocytes, is the most aggressive
malignancy of the skin. The occurrence of melanoma in the light-skinned Caucasian
population has more than tripled in the last 20 years, and currently melanoma stands out
to be the sixth most common cancer in the United States. In the year 2009, around 8650
deaths (5550 men and 3100 women) were reported as a result of melanoma in the United
States (2). A history of skin cancer, presence of multiple benign or atypical nevi,
immunosuppressive treatments, and exposure to ultra violet radiation all predispose to
melanoma development, however, family inheritance still remains the most significant
risk factor for melanoma (4). A meta-analysis conducted to identify inheritance patterns
suggested that the presence of one first degree relative with melanoma increases the risk
by 2.44 fold (5). A search for genetic abnormalities within families affected with
melanoma identified primarily 2 genes (CDKN2A and CDK4) whose mutations are
associated with increased melanoma susceptibility.
The CDKN2A gene located at chromosomal locus 9p21 was found to be mutated,
hyper methylated or deleted in more than 75% of melanoma cell lines (6). The CDKN2a
genetic locus codes for two distinct cell cycle regulatory proteins that are translated in
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alternative reading frames (7). The α transcript encompassing exons 1α, 2 and 3 codes
for p16INK4a cyclin dependent kinase inhibitor while the β transcript (exon 1β, 2, 3)
encodes the protein P14ARF (p19 in mouse) (8-9).
P16INK4a interacts with CDK4 and CDK6 to inhibit the phosphorylation of
retinoblastoma (RB) protein (10). The hypophosphorylated form of RB thus acts as a
tumor suppressor and prevents progression of the cell cycle from G1 to S phase (11-12).
Germline intragenic mutations in the P16INK4a gene were frequently identified in familial
melanoma kindreds and melanoma prone families with an intact ARF function (13-15).
Hence, INK4a is considered the key gene involved in predisposition to familial
melanoma.
P14ARF prevents degradation of p53 by interacting with HDM2 (16) (17-18). The
interaction of p14ARF with HDM2 inhibits the ubiquitin ligase activity of HDM2 on p53
thus preventing its export from nucleus (19). Since ARF is a splice variant of the INK4a
transcript (16), germline mutations of ARF were expected in melanoma patients.
Although insertions and deletions in the ARF exon 1β with an intact INK4a were
reported in a melanoma cell line, germline mutations were not initially identified among
melanoma patients (20). The breakthrough came from two melanoma patients with
germline ARF specific mutations. One patient displayed a 14kB deletion in exon 1β (21),
while the second patient had a 16kB insertion in exon 1β (22) with intact p16INK4a in
either case. Since then melanoma patients were screened for germline ARF mutations.
Later a cluster of 5 different germline mutations was identified in the splice donor site of
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exon 1β with intact INK4a and CDK4 exons (23). These splice variants were expected to
impair ARF function; however, their functional role was not studied (24).
Germline mutations of cyclin dependent kinase 4 (CDK4) have also been
identified in melanoma prone kindreds, however, the frequency of CDK4 mutation is rare
(25-27). The CDK4 gene is present on chromosome 12q13, a region that is not rearranged
or deleted in melanomas (28). Analysis of 31 families with heredity melanoma showed a
CT transition at nucleotide 297 in all 31 families with intact p16INK4a. This CT
transition causes replacement of arginine with a cysteine at position 24 causing the kinase
to be inactive (26, 29). Thus germline mutations or deletions in the CDKN2A or CDK4
loci predispose to melanoma.
Germline mutations in the “melanoma hotspot” genes act as first hit and loss of
heterozygosity is the second and essential step to develop melanoma (30). Environmental
stress in the form of excessive sun exposure is a significant contributing factor in
generating a second level of genetic alterations for carriers of germline mutations since
incidence of melanoma is markedly higher in people living at lower latitudes (31).
It is extremely intriguing how a mutation, for example in the CDKN2 locus,
would primarily increase the odds of melanoma occurrence and not other tumors. To
understand this, the senescence of mouse fibroblasts and melanocytes was studied upon
single and/or double copy loss of the Ink4a/Arf gene. While no effect was identified in
the senescence of fibroblasts upon Ink4a loss, the senescence of melanocytes was
significantly affected with a single copy loss of Ink4a/Arf gene (32) (33). his suggests
that Ink4a/Arf genes are primarily involved in cell cycle regulation. A similar effect was
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observed in human melanocytes, where functional loss of p16INK4a and p14ARF had a
significant effect on melanocyte senescence when compared with human fibroblasts (34).
These results demonstrate the importance of INK4a/ARF genes in controlling regular cell
cycle progression in melanocytes.
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Fig. 1 The CDKN2A locus and cell cycle control.
Exons 1a, 2, and part of 3 combined to form the p16INK4a transcript, while the
exons 1b and 2 form the p14ARF transcript. The p14 protein is shown to inhibit
the function of MDM2 or HDM2, thereby preventing the degradation of p53.
P16INK4a interact with CDK4/6 to prevent the phosphorylation of RB. The hypo
phosphorylated form of RB inhibits cell cycle progression (3)
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Apart from germline mutations, various somatic mutations have been detected in
melanoma patients. The most common somatic mutation present in more than 70% of
melanoma patients are found within the BRAF gene (35). Germline mutations in BRAF
have not been identified in melanoma patients; however, individuals with germline
BRAF mutation develop cardio-facio-cutaneous syndrome, a rare genetic disorder
affecting the face and head structure, but not melanomas (36-38). Among BRAF
mutations, a phosphomimetic substitution in the kinase domain (valine to glutamic acid at
amino acid 600) is the most frequently encountered

(39). Such activating BRAF

mutations were also observed in dysplastic nevi, suggesting that BRAF mutations play a
role in early transformation of melanocytes. (40-43).
Other common mutations in melanoma are found within the phosphatase and
tensin homolog (PTEN) and RAS genes. PTEN protein acts as a tumor suppressor by
regulating the cell cycle through its phosphatase activity (44). PTEN dephosphorylates
phosphatidyl inositol -3-phosphate (PIP3) resulting in the formation of PIP2 (44). This
dephosphorylation is a crucial step that controls the activity of AKT, and loss of PTEN
leads to accumulation of PIP3, thereby increasing AKT activity and cell survival (44).
Allelic loss or altered expression of PTEN contributes to 20% and 40% of melanoma
cases, respectively (45-46), although homozygous deletions are rarely observed.
The RAS (rat sarcoma) subfamily of proteins is small GTPases whose activation
contributes to cell growth, differentiation and survival. Activating RAS mutations are
common in other solid tumors, while only 10-15 % of melanomas carry RAS mutations
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(47). The RAS subfamily consist of KRAS, NRAS and HRAS; among them NRAS
mutations are found in melanomas while KRAS and HRAS mutations are rare (15).
As stated previously, to develop melanoma, more than one genetic alteration is
required. These genetic alterations are either inherited or acquired. In many cases patients
do present multi level genetic abnormalities such as mutations in the both p16INK4a and
BRAF (48). Thus it is evident that the genomics of melanoma is complicated, rendering
the therapy of melanoma quite challenging.
Melanoma therapy and resistance
A key factor in the successful management of melanoma is early detection. Early
malignant melanomas exhibit characteristic features including asymmetry, border
irregularity, color variegation, or a diameter greater than 6 mm. These features are
referred as the ABCD system of diagnosis (49). However, not all early melanomas
exhibit any or all of these characteristic features. Around 5% of all melanomas are not
pigmented and are misdiagnosed as squamous or basal cell carcinoma or inflammatory
lesions (50-51). Early diagnosed melanomas have an excellent prognosis, however the
survival rate drops rapidly once melanomas reach 3mm in thickness (49).
1. FDA approved therapeutic approaches for melanoma
Few FDA-approved treatments are available for metastatic melanoma.
Dacarbazine (DITC) remains the only chemotherapeutic compound commonly used for
metastatic melanoma. DITC targets the cancer cells by alkylating the DNA (52). Other
therapeutics with FDA approval are Interferon-α2b (IFN- α2b) and Interleukin-2. IFNα2b is used for stage III melanoma, showing a 10-20% improvement in patients’ relapse
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free survival. However, it does not show any effect on melanoma related mortality (53).
High dose IL-2 is used for patients in stage IV melanoma. Although short lived, IL-2
treatments are associated with severe toxicities but with 8-10% cure rate for melanoma
(54-55).
2. Therapeutic approaches to target oncogenic pathways
Identification of signaling pathways in melanoma progression have opened up
new areas of research to develop novel therapeutic agents. Discussed below are some of
the key targets that are being explored alone or in combination with chemotherapeutic
agents.
a. The MAP kinase pathway
In several cancers, the RAS-RAF-MAPK-ERK growth-signaling pathway has
gained attention. A RAS farnesyl transferase inhibitor such as Tipifarnib was among the
first of a set of agents that blocks the post-translational modification of RAS proteins,
hence preventing their membrane localization. This drug was taken to phase II clinical
trials in metastatic melanoma patients; however as the response rate was low, further
clinical validation was prohibited (56).
Around 80% of melanoma patients do possess activating BRAF mutations (35,
57). Sorafenib was the initial BRAF inhibitor developed that targeted BRAF, CRAF,
VGEH and PDGF receptor tyrosine kinases (58). Sorafenib showed relatively low
potency towards melanoma when used as a single agent; however, it had a better effect
when combined with other chemotherapeutic agents such as temozolomide or paclitaxel
(59). The need for a more selective BRAF inhibitor led to the development of PLX4032.
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This drug suppressed the activity of BRAFV600E with approximately 30-fold increased
selectivity over the wild type BRAF kinase (60). The drug (61)is currently in phase III
trials and has demonstrated remarkable clinical results (61-62). Unfortunately, melanoma
patients develop resistance after 8-12 months of administering PLX4032. Recent studies
performed to understand the drug resistance observed in melanoma patients has shown
that PLX4032 blocks the growth of tumors that have BRAF mutations by selectively
shutting down the activity of mutant BRAF monomers. Paradoxically, the activity of
normal BRAF kinase in the cancerous and non-cancerous cells was shown to be activated
by this drug. It was shown that this drug transiently elevates the expression levels of
MEK and RAF in cells with wild type RAF, thus facilitating their survival (61, 63-64).
b. MEK kinases and PI3kinase
MEK kinase is downstream of the BRAF signaling pathway. Several MEK
inhibitors have been tested in clinical trials in patients with advanced melanoma.
PD0325901 is currently in phase I trials and the drug specifically inhibits the MEK1/2
mediated signal (65).
It is known that TOR acts as a major effector of the AKT oncogenic signaling
pathway, which is the downstream of PI3 kinase (66-67). Small molecule inhibitor
derivatives of rampamycin, targeting mTOR, demonstrated growth inhibitory effects in
melanoma cell lines. However, similar effects were not observed in the clinical trials (6870).
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c. Cyclin dependent kinases
Mutation or deletion of CDKN2A along with increased activation of CDK2,
CDK4 and CDK6, leads to hyperphosphorylation of RB and increased proliferation of
melanoma tumor cells (15, 71). These findings prompted the development of several
CDK inhibitors. Flavopridol is a well-characterized CDK inhibitor targeting the ATP
binding pocket of CDK2, thereby blocking the G1 exit phase of the cell cycle. It was
shown that this drug also blocks other cell cycle kinases such as CDK1, CDK2, CDK4
and CDK7 (72). This drug induced apoptosis in several cell lines but failed to be effective
when taken to clinical trials (73). Since the cell cycle inhibitors primarily have cytostatic
effects, combining such drugs with chemotherapeutic agents may increase their treatment
efficacy. Other CDK inhibitors at various stages of clinical trials are UCN-01, CYC202,
and BMS387032.
3. Other therapeutic approaches
a. Activation of apoptosis in melanoma cells
It is well known that resistance to apoptosis promotes tumor progression (74).
Normal melanocytes express increased levels of several intrinsic and extrinsic antiapoptotic proteins such as Bcl-xL and X-linked compared to other skin cells as a
protective mechanism against UV-induced insult (75). Consequently, melanoma cells
demonstrated increased resistance to apoptotic death compared to other tumor cells (7677). Hence, attempts were made to induce apoptotic death in melanoma cells by
blocking anti-apoptotic proteins. Oblimersen is an anti-sense agent targeted to
mitochondrial Bcl-2. A phase I/II clinical trial suggested that this drug can sensitize

11
melanoma cells when combined with chemotherapeutic agent decarbazine (78).
However, it did not improve the overall survival of melanoma patients in a randomized
phase III clinical trial (79). The key limitation of this drug is that it can target cells other
than melanoma cells.
b. Blocking of CTLA-4 using monoclonal antibody
Effective T cell activation requires co-stimulatory interaction between B7.1 or
B7.2 on APC and CD28 on T cells (80). Upon activation, T cells increase the expression
levels of CTLA-4. CTLA-4 would then compete for binding with B7 resulting in reduced
TCR stimulation, IL-2 production or T cell proliferation (81-82). Monoclonal antibodies
to CTLA block the interaction between B7 and CTLA4, thereby activating the T cells. As
a result, peripheral tolerance to self-tissue is lost and anti-tumor responses are activated
(83).
Anti-CTLA4 monoclonal antibody ipilimumab is in stage III clinical trials for
metastatic melanoma (82, 84-85) and FDA approval was announced earlier this week.
The main concern with using anti-CTLA-4 antibody is that it can induce septic shock,
since the treatment overrides immune tolerance (86).
In spite of extended research in the field of melanoma therapy, progress has been
limited as the tumor develops resistance to available therapies. This is particularly
devastating for people with a hereditary predisposition to melanoma, since the onset of
melanoma for these patients can occur at an early age (87). Therefore developing a
preventive approach is critical. To design preventive therapies, understanding the
functional role of precursor melanocytes is key.
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Melanocytes and Melanogenesis
Melanocytes are neural crest-derived cells found in the basal layer of the
epidermis (88). Apart from melanocytes, neural crest cells give rise to neurons, glial cells,
adrenal medulla cells and cardiac cells (89). Precursors of melanocytes migrate from the
neural crest to the dermis and finally settle down in the basal layer of the skin and the hair
follicles. Resulting pigmentation patterns differ from species to species (88).
The key function of melanocytes is to protect the skin from harmful UV rays by
producing a complex unstructured pigment called melanin (89). The process of melanin
synthesis is restricted to melanocytes and takes place within lysosome-like organelles, the
melanosomes (89). Depending on skin type, the synthesis of either of two types of
melanin, red/yellow pheomelanin or brown/black eumelanin predominates. The amino
acid

tyrosine

is

the

common

natural

substrate

for

eumelanogenesis

and

pheomelanogenesis (90-91). The process of eumelanogenesis as postulated by Raper and
Mason

(92-93)

involves

dihydroxyphenylalanine)

the

and

conversion

of

successively

to

tyrosine

to

dopaquinone,

DOPA

(3,4-

dopachrome,

dihydroxyindoles, indolequinones and finally to eumelanin (90-91). Pheomelanin is a
reddish-yellow polymeric pigment that is formed from 5-S-cysteinyldopa. The synthesis
of pheomelanin over eumelanin is favored when the intramelanosomal cysteine
concentration is >10−7 M (90, 94). It is interesting to observe that eumelanin and
pheomelanin significantly differ in their chemical structure and physical properties (9596). Upon UV radiation, pheomelanin was observed to generate higher quantities of free
radicals which can eventually lead to cellular lysis (97). This explains why people
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producing increased pheomelanin in their skin have more severe sunburns, thereby
increasing the odds of developing skin cancer due to DNA damage in melanocytes and
keratinocytes.
The process of melanin synthesis involves several enzymes and proteins.
Tyrosinase is the key, rate limiting enzyme of melanogenesis (98). It is a coppercontaining oxido reductase that is involved in the oxidation of mono and dihydric phenols
to their respective orthoquinones (98). The key feature of the tyrosinase active site is that
it has two binuclear copper binding sites that are in close proximity to histidine residues
which assist in the binding of molecular oxygen (1, 99). Depending on the valency of the
copper ions, the active site of tyrosinase exists in oxy or met conformation. In the oxy
conformation, the monovalent copper ions interact with an oxygen molecule yielding a
peroxide. The other conformation, the met-tyrosinase, is the native form of tyrosinase
containing bivalent copper ions and cannot bind with molecular oxygen. Two electron
reduction of met-tyrosinase renders deoxy-tyrosinase in which the copper atoms are in
the Cu(I) oxidation state. Deoxy-tyrosinase readily binds dioxygen and returns the enzyme
to oxy-tyrosinase conformation, which can oxidize phenolic substrates, and the cycle
between de-oxy and oxy conformation continues in presence of oxygen. In case of a
catecholic substrate, oxidation by oxy-tyrosinase returns the enzyme to met conformation.
However, the enzyme returns back to oxy-conformation only in presence of a second
catecholic molecule (1, 94). This could explain why phenolic substrates generate
increased levels of toxic intermediates, while the toxicity is limited to some extent when
catecholic substrates are used.
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Catechol

Phenol

Fig. 2 Schematic diagram showing oxidation of catechol and phenol.
The diagram illustrates that phenol can be oxidized by tyrosinase in the oxy
tyrosinase form, while catechol can be oxidized both by oxy and met tyrosinase
form. Further, the conversion of deoxy and oxy tyrosinase form depends on the
presence of oxygen and is reversible (1). Reproduced with permission.
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Other enzymes and proteins involved in the process of melanogenesis are
tyrosinase related-protein 1 (TRP-1), tyrosinase related protein-2 (TRP-2), melanoma
antigen recognized by T cells (MART-1), and gp100. Tyrosinase related proteins are
known to have similar structural features to tyrosinase such as having a transmembrane
region, and two metal-binding regions, and a cysteine-rich epidermal growth factor motif,
however they have a distinct catalytic role in the biosynthesis of the melanin (100). TRP1 aids in proper folding of tyrosinase via chaperone-type interactions (101) and stabilizes
tyrosinase by interacting with the cysteine-rich epidermal growth factor motif (100). A
mutation in human TRP-1 will affect the activity of tyrosinase as well prevent its export
from the endoplasmic reticulum (100-101).
Tyrosinase-related protein 2 (TRP-2) regulates melanin biosynthesis and
metabolizes the toxic intermediates of the melanin synthetic pathway. The production of
eumelanin versus pheomelanin depends on the enzymatic activity of TRP-2 (102). Active
and accelerated levels of TRP-2 increases isomerization of DOPAchrome to DHICA
thereby favoring the eumelanin production rather than the spontaneous conversion of
DOPAchrome to DHI, which is a toxic intermediate thought to suppress the growth of
cells (100, 102). Production of pheomelanin dominates when TRP-2 levels are lower
because of diminished flow of dopaquinone through dopachrome to eumelanins (102).
Pmel17/gp100 is the scaffold protein that is delivered to the early melanosomes
and undergoes proteolytic cleavage to form the fibrilar structure of melanosomes onto
which melanin is deposited (103-104). MART-1 forms a complex with Pmel17 and its
expression level affects the stability, structure and maturation of melanosomes (103).
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The skin color depends upon the amount of melanin present. It is interesting to
observe how people with lighter skin opt to darken their skin tone using the tanning salon,
and people with a darker skin tone are using depigmenting agents to lighten their skin.
Depigmenting agents are widely used in Asia. Also, it is recommended by dermatologists
for hyperpigmentary skin conditions such as melasma (105).
Depigmenting agents
Depigmenting agents are categorized into two types. The first class of agents
reduces the amount of melanin formation while the second class is cytotoxic to
melanocytes. A number of tyrosinase inhibitors from natural and synthetic sources have
been used extensively as skin lightening agents. Some of the commonly used skin
lightening agents are:
1. Kojic Acid
Kojic acid is the most intensively studied metabolite of the fungus Aspergillus
oryzae. kojic acid blocks melanin synthesis by chelating the copper sites in tyrosinase
enzyme, thereby inhibiting its phenolase activity. It is used extensively in the food
industry to prevent the browning reaction of various food products and in the cosmetic
industry to lighten the skin tone (106-108).
2. Flavanols
Flavanols are generally isolated from plants and most of them are found to be
tyrosinase inhibitors. Flavanols competitively inhibit the oxidation of L-DOPA and act as
a copper chelator in the active site of the tyrosinase enzyme (109-110). Some of the
flavanols acting as tyrosinase inhibitors are nobiletin (5,6,7,8,3',4'-hexamethoxyflavone),
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naringin

(5,7,4'-trihydroxyflavanone),

and

neohesperidin

(5,7,3'-trihydroxy-4'-

methoxyflavone). However, the inhibitory strength of different flavanols were found to
be less in comparison with with kojic acid (111-112).
Other skin lightening agents that are commonly used in the cosmetic industry
include hydroquinone, soy, glabridin and glycolic acid. These agents are also tyrosinase
inhibitors, and are involved in reducing the melanin content (113-114).The efficacy of
depigmenting agents depends on how close they mimic substrates of the melanogenic
pathway, in particular tyrosine. Competitive inhibition of tyrosinase is a common factor
for skin lightening agents and melanotoxic agents; however, it has not been clarified how
depigmenting agents mediate toxicity towards melanocytes. It has been hypothesized that
melanotoxic depigmenting agents would be converted to reactive orthoquinones by
tyrosinase, thus leading to destruction of melanocytes (115). Some of the agents that are
reported to compete with tyrosine as well as mediate toxicity in melanocytes are 4hydroxy anisole, curcumin, and 4-tertiary butyl phenol (116-117). Recently, the
underlying mechanism of tyrosinase-catalyzed conversion of phenolic substrates was
modeled using the FDA-approved depigmenting agent, mono-benzyl ether of
hydroquinone (MBEH). MBEH was shown to interact with mushroom tyrosinase and
generate reactive ortho-quinones, thereby destructing the melanocytes (118). Further, the
unstable ortho-quinones were shown to undergo dimerization or coupling with thiol
compounds such as glutathione, or with proteins such as bovine serum albumin. These
mechanism might bear relevance to the pathogenicity of vitiligo where the tolerance to
melanocyte antigens is lost (115). The hypothesis is that the oxidized quinones have a
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greater tendency to bind with melanogenic enzymes.Binding of these small molecules to
larger proteins alters their structure, thereby generating neoantigens and breaking
immune tolerance. Since the process of melanogenesis is common between melanocytes
and melanoma cells, it was proposed to target melanoma cells using cytotoxic
depigmenting agents.
Pro-Drug therapy using melanogenesis pathway
Oxidation of phenols to orthoquinones is an essential step in the process of
melanogenesis (98). Orthoquinones are highly reactive molecules and can covalently
bind with proteins and nucleic acids (119). Limiting the diffusion of quinones (such as
dopaquinone) with hydrophilic side chains through the melanosomal membrane, rapid
cyclization of the orthoquinones to reduce the accumulation of toxic intermediates, and
increasing the activity of melanosomal enzymes such as TRP-2 are some of the ways by
which melanocytes regulate quinone toxicity (102, 119). Researchers explored abovementioned regulatory mechanisms to design pro-drugs for targeting melanoma cells. Prodrugs are inactive precursors that are metabolized or activated in the body to release or
generate the active drug, preferably at the target site (1). Ideally, pro-drugs for melanoma
therapy should evade hepatic metabolism, reach the tumor tissue, enter melanosomes to
be oxidized to toxic quinones, re-enter the cytoplasm of melanoma cells and activate
cellular lysis.
Two concepts were used to design pro-drugs targeting melanogenesis. They are
referred to as the ‘Achilles heel approach’ and the ‘Trojan horse approach’. The
‘Achilles heel approach’ involves the use of tyrosine analogs with bulky side chains to
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maximize the formation of orthoquinone intermediates by preventing the cyclization
reaction. Since melanoma cells have a porous melanosomal membrane (120), it was
thought that the newly formed toxic intermediates would be released in to the cytosol.
Among various compounds that were tested, 4-hydroxy anisole was found to be oxidized
by tyrosinase into 4-methoxycatechol. The oxidized product was found to be cytotoxic to
melanocytes and melanoma cells, and pilot clinical studies were conducted in melanoma
patients (121-125). Unfortunately, the clinical trials had to be terminated as the as the
pro-drugs themselves are toxic to other cell types, thus causing liver and renal toxicity.
(126-127).
In search of new cytotoxic agents, Fujita et al found that pheomelanin precursor
5-cystenyldopa is more effective than dopa in inhibiting melanocyte growth and
proliferation (128). Subsequently, several new compounds were synthesized and assayed
for toxicity towards melanoma cells (129-130). Among tested compounds, 4Scysteaminylphenol (4S-CAP) induced significant depigmentation (80%) in guinea pigs,
showed specific toxicity to melanin containing cells and prolonged the life of B16 tumor
bearing mice (131-133). Further studies with radio-labeled 4S-CAP showed selective
incorporation of the chemicals in tumors generated after challenging the mice with B16
melanoma cells (134). In spite of these promising results, the limited solubility and low
LD50 have thus far prevented the use of 4S-CAP in vivo.
In the field of cancer hyperthermia, cancer cells displayed a 10-fold increased affinity for
positively charged magnetic nanoparticles compared with uncharged nanoparticles. These
positively charged magnetic particles were then heated using an alternating magnetic
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field to kill the target cells. In order to attain specificity, a similar approach was recently
applied where 4S-CAP loaded magnetic cationic liposomes (MCL) were used
therapeutically. Intratumoral injection of 4S-CAP loaded MCL was performed in B16challenged mice and melanoma nodules were heated using an alternating magnetic field,
thereby regressing the tumor volume

(135). Due to extreme toxicity of 4S-CAP,

derivatives of 4S-CAP are currently being screened to identify a less toxic compound
with similar specificity. Some potential candidates are N-AC-4CAP (N-acetyl-4-Scysteaminylphenol) and N-propionyl-4-S-cysteaminylphenol (N-Pr-4-S-CAP). Similar to
4S-CAP, its derivatives were reported to be specifically toxic to cells with tyrosinase
activity, and further studies are being conducted (136-138). A key problem for the
Achilles heel strategy is that the rate constant for the reaction of ortho-quinones with
thiols exceeds that of other reactions (139). The cytotoxicity induced by modified
substrates is dependent on depletion of thiols, more specifically glutathione (GSH),
which is present in the cells at concentrations in the millimolar range. Although the idea
of designing pro-drugs to target the melanogenesis pathway is unique, progress is
hampered by the toxicity of the prodrugs themselves, and targeting these compounds to
metastatic melanoma tumor remains a challenge.
The ‘Trojan horse’ is a tale in the Trojan war, where Greek soldiers entered the
city of Troy by hiding in a huge horse. In the melanoma pro-drug therapy context, the
anti-cancer drugs are tagged onto (hidden by) dopaquinone, the natural substrate of
tyrosinase. Once the substrate becomes oxidized by melanogenic enzymes, the hidden
anti-cancer drugs are released in to the melanoma cells and melanocytes. Since this
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approach uses the natural substrate of melanin synthesis, the oxidized ortho quinone
undergoes intramolecular cyclisation. Thus, the oxidized products would not induce
toxicity while the newly released anti-cancer drugs would target the melanocytes and
melanoma cells. Agents such as

phenol mustard, bis-ethylamine mustard and

daunorubicin (daunomycin) have been tagged onto melanogenic substrates (117). This
approach provides an built-in drug delivery mechanism selective for melanoma cells.
Since melanoma cells express different levels of melanogenic enzymes, targeting every
melanoma cells by this approach may be difficult to achieve.
Thus, it is clear that harnessing the melanogenic pathway for melanoma treatment is
difficult to achieve, since the depigmenting agents should be used systemically to target
the metastatic tumors. However, it would be interesting to explore the prophylactic
potential of these depigmenting agents.
Modes of cell death
Cell death can be categorized in to three major types: apoptosis, necrosis and
autophagy. Apoptosis is a programmed cell death exhibiting unique characters such as
membrane blebbing, cell shrinkage, chromatin compaction, DNA fragmentation (140).
The process of apoptotic death can be initiated by an external or internal signal. Upon
initiation, specific enzymes known as caspases would be activated (140). Caspases are
cysteine proteases that are in an inactive form and are activated upon death signal. In
humans three major class of caspases do exist. They are known as initiator (caspase -8, -9,
and -10), executioner (caspase -3, -6, -7), and inflammatory (caspase-1,-4,-5, -11, and 12). The initiator caspases would form complex with adaptor proteins and would undergo
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self-proteolysis that would activate the downstream executioner. Inflammatory caspases
are primarily involved in cleaving cytokines involved with inflammatory responses (141) .
Autophagy is the second mode of cell death where cellular organelles were
degraded by autophagic vesicles. The two-membrane vesicles were formed in the
endoplasmic reticulum, engulf the cellular contents, and fuse with lysosomes to degrade
the cellular contents. PI3 kinase pathway have been involved in the process of autophagy,
however the complete process is yet to be identified (140).
The third mode of cell death is necrosis where cells undergo a sudden trauma,
infection or inflammation. A necrotic cell death exhibit cellular swelling, rupture of cell
membrane and release of cellular organelles. Although necrosis is generally defined as
un-programmed cell death, studies have identified that mitochondrial swelling, lysosome
rupture with activation of calpain and cathepsin have been identified in necrotic death
(140).
Need for prevention
Removal of precursor tissue or precursor cells that can otherwise undergo
malignant transformation is a concept for preventive treatment. For example, women
with germline mutations within the BRCA genes are at a high risk of developing breast
or ovarian cancer (142). Such women sometimes undergo elective surgery as a preventive
measure towards potential future cancer development (143). Such surgical intervention is
not feasible for familial melanoma patients as the precursor cells (“melanocytes”) are
dispersed throughout the skin. However, specific removal of melanocytes from the skin
by methods similar to those described above can potentially serve as a prophylactic

23
treatment, similar to elective mastectomy for women predisposed to breast cancer.
Inducing a vitiligo like condition would then serve as a potential preventive treatment for
familial melanoma, since an intriguing dichotomy exists between vitiligo and melanoma.
Vitiligo and melanoma-striking similarities
Vitiligo is an autoimmune disease affecting 0.5% of the world population (144145). The association of vitiligo with other autoimmune diseases like Hashimoto's
thyroiditis suggested the involvement of an immune response in the pathogenesis of the
disease. It is extremely interesting to find striking similarities between vitiligo and
melanoma.
Vitiligo is most devastating to ethnicities associated with darker skin tones, where
the contrast between unaffected and lesional skin is highly apparent. Melanoma on the
other hand, preferentially frequents people of lighter skin tones. Whereas more males
than females are struck by melanoma, vitiligo is more prevalent among females
(unpublished observation). The etiology of either disease involves a hereditary
component. In vitiligo this is supported by the fact that approximately 50% of patients are
able to identify first degree relatives with the disease (146), whereas familial melanoma
has been assigned to particular genes including the Ink4A/Arf genes encoded on
chromosome 9 (147). Loss of melanocytes from the epidermis in vitiligo is associated
with immune infiltrates in actively depigmenting skin, consisting of T cells with a
decreased CD4/CD8 ratio, dendritic cells and macrophages (145). These T cells are, at
least in part, responsive to melanosomal antigens also targeted by T cells infiltrating
melanoma tumors and targeted by tumor vaccines in clinical trials (145, 148). Melanoma
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patients responding to vaccine therapy may experience secondary depigmentation, which
is considered a positive prognostic factor reflecting activated immune responses to the
tumor (149). On the other hand, T cells isolated from vitiligo patient skin can express a
higher affinity for their cognitive antigen than tumor infiltrating T cells. This renders
vitiligo T cells an optimal source for the development of transgenic TCR based therapy
for melanoma (150). The curious observation that the same melanosomal antigens are
optimal target molecules for cytotoxic T cells in either disease drives the concept that
vitiligo may offer protection from subsequent development of melanoma. This is the
fundamental ground for inducing vitiligo in melanoma patients as proposed in this project.
As the development of melanoma can predispose patients to vitiligo, epidemiologic data
will not necessarily reveal such protective effect (151).
Novel chemopreventive therapy using topical bleaching phenols
The melanogenic pathway offers a unique means of generating toxic compounds
specifically in cells of the melanocyte lineage with great potential towards the treatment
of melanoma. As explained above, systemic use of melanotoxic agents for melanoma
therapy led to renal and liver toxicity (121). Therefore, these phenolic agents are better
used in melanoma therapy by topical application. However, melanoma tumors themselves
were fully resistant to these treatments. Generally, tumor cells were known to have
increased levels of ATP-dependent ABC transporters that offer protection against various
therapies by pumping out the toxic drugs that affect their growth (152). This suggests that
melanoma cells can pump the prodrugs or subsequently generated toxic quinones out of
the cell, thereby developing resistance. Similar observations were made by van den
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Boorn et al, where topical treatment of MBEH alone on C57BL/6 mice in a therapeutic
setting did not have any effect on already established B16 melanomas (153). Hence,
using topical phenolic agents to target melanocytes rather than melanoma cells will better
serve as a preventive treatment for people with a predisposition to melanoma, and those
at risk for recurrent disease.
Phenolic agents 4-tertiary butyl phenol (4-TBP) and mono benzyl ether of
hydroquinone (MBEH) were initially identified as causative agents in vitiligo-like
pathogenesis (154-155). Although 4-TBP and MBEH were reported to induce
depigmentation, it was not known whether these agents are toxic to melanocytes. In vitro
studies revealed that 4-TBP is specifically cytotoxic to melanocytes in comparison with
keratinocytes, while fibroblasts displayed a similar level of sensitivity (156). Additionally,
4-TBP was shown to induce apoptotic destruction of melanocytes (116). Since 4-TBP
mimics the structure of tyrosine, it could subsequently be demonstrated that 4-TBP
competitively inhibits tyrosinase activity at concentrations that

do not impact on

melanocyte viability (116).
Currently, MBEH is the only FDA approved drug within US to remove remaining
pigmentation in advanced vitiligo patients in order to maintain a uniform skin tone (157).
However, its working mechanism is not known.
The aim of this project is to identify whether topical depigmenting agents can
be used in the prophylactic treatment for people with a predisposition to melanoma.
Such protection can be offered in a two-tiered approach by eliminating precursor cells of
the melanocyte lineage that can otherwise malignantly transform and by eliciting an

26
immune response to distant melanocytes not directly exposed to bleaching agents, as well
as to melanoma cells that share expression of melanocyte differentiation antigens.
These questions will be addressed in the following chapters.
Chapter 2 describes whether MBEH is cytotoxic specifically to melanocytes.
Following this, the mode of cell death mediated by MBEH is identified in comparison
with bleaching agent 4-TBP. Further, the potential involvement of melanogenic enzymes
in depigmentation is addressed by correlating sensitivity to MBEH with basal expression
levels of melanogenic enzymes and melanin content among melanocyte monocultures.
Finally, this study serves to understand whether treatment with bleaching agents would
generate reactive oxygen species in an in vitro setting.
In Chapter 3, the immune aspects mediated by 4-TBP and MBEH are studied in
human explant cultures followed by treatment of wild type and k14-SCF mice. The
immune effects of bleaching agents 4-TBP and MBEH were studied initially in normal
human skin, in order to quantify Langerhans cell emigration in response to either agent.
Following this, the infiltration of immune cells was studied in the mouse skin upon upon
bleaching agent induced depigmentation. Finally, the nature of the immune response
mediated by MBEH was identified by assessment of cytokine profiles in the treated skin.
In Chapter 4 attempts to generate a spontaneous pigmented melanoma mouse
model are described. This was attempted by crossing Tyr HRAS- Ink4a/Arf-/- albino
mice (generating non-pigmented tumors) and k14-SCF epidermally pigmented mice. The
features of resulting offspring were tested by genotyping, following tumor development
and assessing melanoma marker expression in resulting tumors. Finally, the immune
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component of anti-tumor effects mediated by MBEH was tested by pre-treating k14-SCF
mice and challenging them with B16 melanoma tumors.
Chapter 5 contains the discussion section of all work performed and provides the
overall conclusions of this study, as well as describing potential follow up studies to
newly arising research questions.
In conclusion, this study explores novel prophylactic treatment opportunities
using topical bleaching agents 4-TBP and MBEH of potential use for people with a
predisposition to melanoma.

CHAPTER II
WORKING MECHANISM OF MBEH

Abstract
Monobenzyl ether of hydroquinone (MBEH) is an FDA-approved drug used for
depigmentation therapy of advanced vitiligo. Here, the working mechanism of MBEH is
explored in comparison to 4-tertiary butyl phenol (4-TBP), a known causative agent for
occupational vitiligo mediating apoptotic melanocytic death. Cytotoxic experiments
reveal that similar to 4-TBP, MBEH induces specific melanocyte death. To compare
death pathways initiated by 4-TBP and MBEH, classical apoptotic hallmarks were
evaluated in treated melanocytes. MBEH induced cell death without activating the
caspase cascade or DNA fragmentation, demonstrating that the death pathway is nonapoptotic. Release of HMGB1 by MBEH-treated melanocytes and ultrastructural features
further confirmed a necrotic death pathway mediated by MBEH. A negative correlation
between MBEH-induced cell death and cellular melanin content supports a cytoprotective
role for melanin. Moreover, MBEH exposure upregulated the levels of melanogenic
enzymes in cultured melanocytes, whereas 4-TBP reduced the expression of the same.
Further, generation of reactive oxygen species was observed only upon MBEH treatment.
In summary, exposure to MBEH or 4-TBP has profoundly different consequences for
melanocyte physiology and activates different death pathways. As the mode of cell death
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defines the nature of the immune response that follows, these findings help to explain the
relative efficacy of these agents in mediating depigmentation.
Introduction
Vitiligo, a chronic pigmentary disorder, results from a T-cell mediated
autoimmune response towards melanocytes (158). Patients with advanced vitiligo can opt
to biochemically remove remaining pigmentation (159). For depigmentation therapy, new
methods are gradually becoming available including the use of 4-methoxy phenol
combined with Q switched ruby laser or cryotherapy (160). However, monobenzyl ether
of hydroquinone (MBEH) remains the only drug FDA approved for depigmentation
therapy within the United States (157). The working mechanism of MBEH remains
unexplored, although MBEH is believed to remove melanocytes from the skin as it
generally mediates permanent depigmentation (157). However, in some patients
repigmentation has been observed after treatment (161).
The depigmentation process that follows exposure to phenolic agent 4-tertiary
butyl phenol (4-TBP) is better understood. In vitro studies have shown that 4-TBP is
specifically cytotoxic to melanocytes. Though 4-TBP is a tyrosine analog that binds the
catalytic site of the tyrosinase enzyme and acts as a competitive inhibitor of tyrosinase
(162), the cytotoxic effects were found to be independent of tyrosinase activity (156, 162).
The latter studies revealed that sensitivity of melanocytes to 4-TBP instead correlates
with the level of tyrosinase-related protein 1 (TRP-1) expressed by melanocytes (163).
Normal melanocytes were shown to down-regulate the levels of microphthalmia-
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associated transcription factor and TRP-1 in response to 4-TBP as a protective
mechanism (163). Finally, 4-TBP is shown to activate apoptosis in melanocytes (156).
Phenolic agents like 4-hydroxyanisole, 4-TBP, and MBEH are thought to be
oxidized and converted to reactive orthoquinones upon interacting with tyrosinase (115).
Recent studies by Manini et al have shown that MBEH can bind with mushroom
tyrosinase and generate ortho-quinones (118). Therefore, it can be expected that phenolic
agents can generate reactive species in melanocytes.
The two main categories of cell death are apoptosis and necrosis. Apoptosis is a
well defined and programmed cell death with classical hallmarks such as membrane
blebbing, nuclear fragmentation, activation of the caspase cascade and changes in
mitochondrial permeability (164). As an early signal, cells undergoing apoptosis display
surface expression of phosphatidyl serine and are opsonized for phagocytosis by
phosphatidyl serine receptor expressing macrophages (165-166). Alternatively, necrosis
is an unregulated form of cell death characterized by cytoplasmic swelling and
disintegration of the plasma membrane and cellular organelles (164). Necrotic cells
stimulate an inflammatory response by releasing immune stimulatory agents like DNA
binding High Mobility Group Box-1 protein (HMGB1) and heat shock proteins (167168), and necrosis is therefore considered a strong inducer of immune responses (168).
The current study is focused on understanding whether MBEH intersects with the
melanogenic pathway and mediates selective cytotoxicity to melanocytes by in vitro
cytotoxicity assays using melanocytes, fibroblasts and keratinocytes isolated from human
skin. The appearance of apoptotic hallmarks in response to chemical exposure was
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assessed by FACS analysis of surface phosphatidyl serine expression as an early
apoptotic marker. Activation of the caspase cascade was assessed by western blotting and
fluorimetric assays to identify products of caspase-3 and PARP cleavage. Possible
alternative modes of cell death were followed by electron microscopic comparison of
cultured cells exposed to 4-TBP or MBEH followed by analysis of HMGB1 release in
supernatants of treated cells. Studies were expanded to include a model more closely
mimicking human skin; DNA fragmentation was analyzed by TUNEL staining of
organotypic skin cultures. Further, the potential involvement of melanogenic enzymes in
depigmentation was assessed by correlating sensitivity to MBEH with basal expression
levels of melanogenic enzymes and melanin content among melanocyte monocultures,
measured by FACS analysis and a standard quantitative melanin assay. Changes in the
expression levels of melanosomal markers upon treatment with 4-TBP or MBEH were
identified by FACS analysis of cultured cells. Finally, this study would also understand
whether treatment with bleaching agents would generate reactive species in an in vitro
setting. Besides a further understanding of the consequences of topical exposure to
bleaching agents per se, the current investigations shed light on the potential of these
agents to achieve complete and permanent depigmentation of the skin in vitiligo patients.
Materials and methods
Cell culture
Cultures of normal human melanocytes, keratinocytes and fibroblasts were
established from otherwise discarded foreskin tissue obtained after routine circumcision
from the University of Chicago and Loyola medical center. All studies performed with
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human tissue were carried out in adherence with the Declaration of Helsinki and were
approved by the Institutional Review Board of the institution where circumcisions were
performed. Dermo-epidermal separation was performed by incubation with 0.5 mg/ml
thermolysin (Sigma, ST Louis, Mo). Epithelial cells were further separated by incubation
in 0.1% trypsin. Cells or dermal tissues were plated in keratinocyte, melanocyte or
fibroblast growth media.
Normal human melanocytes were cultured in Ham’s F-12 medium (Media TechHerndon VA) with 2mM Glutamine (Invitrogen, Carlsbad, CA), 100 IU/ml penicillin,
100 µg/ml streptomycin 100 µg/ml amphotericin (Invitrogen), 0.1 mM IBMX (Sigma),
10 ng/ml TPA (Sigma), and 1% Ultroser G (Pall Biosepra- Cergy, France).
Normal human dermal fibroblasts were cultured in DMEM (Media-Tech,
Herndon, VA) with 10% heat-inactivated fetal bovine serum (Gemini Bio-products, West
Sacramento, CA), 100 IU/ml penicillin, 100 µg/ml streptomycin and 100 µg/ml
amphotericin (Media Tech).
Normal human keratinocytes were cultured in growth medium with M154 basal
medium (Cascade Biologicals, OR), supplemented with human keratinocyte growth
supplements (Cascade Biologicals) with 100 IU/ml penicillin, 100 µg/ml streptomycin,
100 µg/ml amphotericin (Invitrogen) and immortalized with HPV16 E6 and E7 retroviral
constructs as described previously to allow prolonged passaging (169).
Organotypic culture
Organotypic culture was performed as described previously (170). In brief, 6mm
biopsies were punched from otherwise discarded foreskin tissue obtained after routine
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circumcision. The explants were cultured in Dulbecco's Minimal Essential Medium
containing 10% inactivated normal human serum at the air-liquid interphase in 0.4
micron transwell plates with epidermal side facing up (Corning, Teterboro, NJ). After
treatment with 5µl of 250mM of 4-TBP or MBEH for 24 hours, explants were embedded
in OCT (Sakura Finetek USA, Torrance, CA) and snap-frozen for future sectioning. All
studies performed with human tissue were carried out in adherence with the Declaration
of Helsinki and were approved by the Institutional Review Board of the institution where
circumcisions were performed.
Cytotoxicity Assay
Cell viability was measured by MTT assays (Bioassay system, Hayward, CA)
according to manufacturer’s instructions. In brief, 20,000 cells/well were plated in
triplicate wells of a 96 well plate to attach overnight. Cells were treated either with
vehicle alone or with 250 µM, 500µM or 900 µM of 4-TBP or MBEH for 24 hours. 4TBP (Sigma) was prepared as a stock solution of 250 mM in 70% ethanol. MBEH
(Sigma) was dissolved in 20% DMSO and mixed with 70% ethanol for a stock
concentration of 250 mM. The use of a vehicle control refers to the use of 20% DMSO in
70% ethanol. MTT reagent ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, a tetrazole) was added to the cells and incubated in a 37C humidified chamber
for 4 hours. Tetrazole is converted to formazan in mitochondria of living cells. The
formazan crystals formed were dissolved in solubilization buffer and the absorbance was
read in a spectrophotometer at a wavelength of 562 nm (BMG Labtech Inc, Durham, NC).
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Cell viability was calculated as a percentage of absorbance of the samples relative to
untreated controls.
Apoptosis assay - Flow cytometry
Cells were stained using an annexin-V-FITC Apoptosis Detection Kit (Invitrogen)
according to the manufacturer’s instructions. Briefly, equal numbers of melanocytes
(Mf0639 P4) were plated and treated with 500μM or 900μM of 4-TBP or MBEH for one
hour. Floating and adherent cells were combined and subsequently incubated for 15
minutes with annexin-V-fluorescein isothiocyanate and propidium iodide (PI). Cells were
acquired with a FACScanto (Becton Dickinson, SanJose, CA, USA) and analyzed with
Flowjo software (TreeStar, Ashland, OR). Cells in the FITC-positive and PI-negative
fraction were quantified as apoptotic cells.
Fluorogenic substrate assay
Caspase-3 activity was quantified using a fluorogenic substrate. Briefly, equal
amounts of cultured melanocytes (Mf0861, P4) were treated with 500μM or 900µM of 4TBP or MBEH for 1 hour. Cells were then lysed in 50µl of lysis buffer (25mM HEPES,
10% sucrose, 0.1% CHAPS, and 2mM EDTA) and protein concentrations were
determined by Bradford assays. An equal amount of protein was mixed with assay buffer
(25mM HEPES, 5mM DTT, and 100 µM of substrate Ac(N-acetyl)-DVED-AFC (7amino-4-trifluromethylcoumarin) and the reaction was incubated at 37ºC for 2.5 hours.
Fluorescence was determined as a measure of caspase-3 activity in a cytofluor multi-well
plate reader with 360nm as excitation and 530nm as emission wavelengths (Invitrogen).
The enzyme activity was reported as nmoles/mg protein/hour.
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Western Blots
To investigate the expression level of pro- apoptotic factors, melanocytes cells
were treated with 500μM or 900uM of 4-TBP or MBEH for 1 hour. Vehicle treated cells
served as control. Cells were washed in PBS and incubated in lysis buffer (50nM Tris,
2mM ethylene diamine tetracetic acid (EDTA), 150mM NaCl, and 1% Triton-X-100) in
presence of a protease inhibitor cocktail (Roche, Indianapolis, IN). Cell extracts were
spun and protein content was estimated in the supernatant according to manufacturer’s
instructions using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA). Cellular
proteins were electrophoresed in a 10% polyacrylamide gel and were transferred to a
PVDF membrane (Millipore, Billerica, MA). The blots were incubated with a rabbit
polyclonal anti-caspase-3 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA), a
rabbit polyclonal anti-PARP antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA),
or a mouse monoclonal anti-HMGB1 antibody (Novus biologicals, Littleton, CO) as well
as with monoclonal anti-GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)
(Chemicon, Temecula, CA). Biotinylated antimouse IgG (Dako) or anti rabbit IgG (Santa
Cruz Biotech Inc, Santa Cruz, CA) antibodies were added followed by peroxidase labeled
streptavidin (Dako, Carpinteria, CA). Peroxidase activity was detected by ECL
chemiluminesence in a film imager (Fuji, Stamford, CT).
Electron Microscopy
For ultrastructural studies melanocytes were seeded in multi-well Lab-Tek
chamber slides (Nunc, Naperville, IL). Adherent cells were processed for electron
microscopy as previously described (171). Briefly, cells were fixed in wells with half-
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strength Karnovsky's fixative in 0.2 M sodium cacodylate buffer at pH 7.2 for 30 min at
room temperature. Cells were then treated with 1% osmium tetroxide containing 1.5%
potassium ferrocyanide for 30 min and stained en bloc with 0.5% uranyl acetate for 30
min, dehydrated, and embedded in Eponate 12. Three areas of each culture were cut out
of the Epon cast, mounted on Epon pegs, and sectioned on an RMC MT 6000-XL
ultramicrotome. Ultra thin sections were then stained with aqueous solutions of uranyl
acetate (2%) and lead citrate (0.3%) for 15 min each, and viewed and digitally
photographed using a JEOL JEM-1230 transmission electron microscope. Tissueprocessing supplies were purchased from Ted Pella (Tustin, CA, U.S.A.).
TUNEL labeling
Six millimeter biopsies obtained from skin tissue were cultured and treated as
described under the organotypic culture heading. Unfixed 8 µm cryosections were
initially incubated with primary antibody M2-9E3 to MART-1 (Covance, Dedham, MA).
Sections were then fixed in 1% paraformaldehyde and stained for DNA fragmentation
using an ApopTag Fluorescein In Situ Apoptosis Detection Kit (Chemicon- Temecula,
CA) according to the manufacturer’s instructions. In brief, sections were incubated with
dioxygenin-labeled oligonucleotides in presence of TdT enzyme to extend the 3’OH
breaks of the DNA. Fluorescein isothiocyanate (FITC)-labeled nucleotides were added,
followed by phycoerythrin (PE)-labeled streptavidin (Dako, Carpinteria, CA). The
sections were analyzed by confocal analysis with a Zeiss LSM-510 microscope (Zeiss,
Thornwood, NY) after counterstaining with 4', 6-diamidino-2-phenylindole (DAPI)
(Invitrogen). DAPI fluorescence was identified at 405 nm using a Diode laser. PE was
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monitored using a HeNE 633 laser. Detection of FITC was performed using a multilineargon laser excited at 488nm.
Intracellular staining
Melanocytes treated with 250 µM of 4-TBP or MBEH for 72 hours were lifted
with 0.5 mM EDTA. For permeabilization, cells were fixed in 2% paraformaldehyde and
washed with 0.03% saponin. The cells were incubated for 1 hour at 4º C with monoclonal
antibody Ta99 to TRP-1 (Covance, Dedham, MA), goat polyclonal antibody D-18 to
TRP-2 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), monoclonal antibody T311 to
tyrosinase (Neomarkers, Fremont, MA) prepared in 0.3% saponin. Biotinylated anti
mouse IgG (Dako) or anti goat IgG (Santa Cruz Biotechnology Inc.) was used as
secondary antisera followed by PE labeled streptavidin (Dako). Flourescence data were
acquired with a BD FACScanto flow cytometer (Becton Dickinson) and analyzed with
Flowjo software (TreeStar).
Measurement of reactive oxygen species
2’,7’Dichlorodihydroflorescein diacetate (H2DCFDA) (Molecular probes, CA), is
a cell- permeable nonfluorescent compound. Upon oxidation by reactive oxygen species,
H2DCFDA emits green flourescence (517-527nm) when excited by a blue light(.492495nm) Melanocytes (Mf0639) were plated in 96 well plates at 10,000 cells/ well
(Corning, Teterboro, NJ). Cells were treated with 25μM of H2DCFDA reconstituted in
melanocyte media and incubated for 45 minutes at 37oC. After incubation, cells were
washed with PBS, treated with 500 and 900μM of 4-TBP or MBEH, and followed over
time for ROS generation. Emission of green fluorescence at 530nm was quantified and
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the amount of ROS generation was calculated at different time points. Treatment with
100μM of H202was used as a positive control.
RESULTS
Cytotoxicity quantification
The viability of cultured human primary melanocytes, fibroblasts and
keratinocytes was determined through MTT assays after treating with 250 µM, 500 µM
and 900 µM of 4-TBP or MBEH for 24 hours. In Fig.3, data are shown for a
representative experiment of 2 performed. Vehicle treatment served as a control for all
cell types. In Fig.3a, the viability of melanocytes was reduced by 26 % and 67 % in
response with 250 µM and 500 µM of 4-TBP respectively. Upon 250 and 500 µM
concentrations of MBEH treatment, the viability of melanocytes was reduced by 43 %
and 77 % respectively as shown in Fig.3b, indicating an increased potency of MBEH in
comparison with 4-TBP. Surprisingly, fibroblasts and melanocytes were equally sensitive
to both treatments, yet keratinocytes were significantly more resistant to both treatments
at 250 or 500 µM concentrations. The viability of keratinocytes remained unchanged
upon 250 µM exposure, while at 500 µM the viability was reduced only by 21 % and
31 % upon 4-TBP and MBEH treatment respectively. Thus, both bleaching phenols are
selectively cytotoxic to melanocytes among epidermal cells. Finally, at the highest
concentration viability was not observed in any cell type for either treatment.
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Fig. 3 Cytotoxicity of MBEH and 4-TBP towards cutaneous cells
Epidermal foreskin derived melanocytes Mf0814 P5, Mf0932 P2, Mf0883 P3 and
Mf0929 P3 with respective melanin contents of 55.0, 10.7, 8.1, and 28.4 pg/cell,
fibroblasts (Ff0201 P4) and keratinocytes (Kf0180 P14) were treated with 250, 500 or
900 µM of 4-TBP (Fig.3a) or MBEH (Fig.3b) for 24 hours. The percent viability was
calculated through MTT assays. Mean and SD were calculated and statistical significance
was evaluated by Student’s T test where ‘*’ indicates p<0.05 and ‘**’ indicates p<0.01
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for melanocyte viability in comparison with keratinocytes after 250 and 500 µM
treatment of 4-TBP and MBEH treatment.
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Analysis of annexin-V staining
Melanocytes treated with 4-TBP or MBEH (500 or 900 µM for 1 hour) were
stained with FITC-labeled antibody to annexin-V along with propidium iodide. PIpositive cells were gated out and the percentage of apoptosis was estimated in live cells.
At 900 µM of 4-TBP, melanocytes revealed a substantial apoptotic population (18.4%) as
shown in Fig. 4. Since melanocytes are more sensitive to MBEH than to 4-TBP as shown
in Fig.1, data are included for 1 hour treatment with both 900 and 500 µM of MBEH to
ensure that apoptosis is not induced at a lower concentration of the drug. Fig. 2 further
confirms that no apoptosis was observed upon treatment with MBEH. Cells treated with
vehicle alone served as controls for both treatments.
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Fig. 4 AnnexinV staining of MBEH and 4-TBP treated cells
Melanocytes were treated with 500 or 900 µM of 4-TBP or MBEH (solid line) or vehicle
alone (grey line) for 1 hour. FACS analysis of annexin-V staining, gating out PI stained
(dead) cells, demonstrated that 4-TBP but not MBEH induced apoptotic cell death.
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Caspase-3 and PARP detection
Cleavage of caspase-3 is a critical indicator of the apoptotic cascade. To quantify
the enzymatic activity of caspase-3, cell extracts pre-treated with either agent for 1 hour
were incubated with a synthetic caspase-3 peptide substrate that emits fluorescence upon
cleavage. In a representative experiment shown in Fig. 5a, MBEH treatment did not
impact the level of caspase-3 activity in comparison with vehicle treatment at either
concentration used. However, melanocytes treated with 4-TBP significantly increased
caspase-3 activity in response to the 900 µM concentration (p<0.05). Western blot
analysis shown in Fig. 5b further confirmed that MBEH treatment did not induce
caspase-3 cleavage, whereas 4-TBP treatment did induce cleavage of pro-caspase into
active caspase. Cleavage of poly (ADP-ribose) polymerase (PARP), a downstream target
of caspase-3 was similarly evaluated by western blotting. As expected, PARP cleavage
was observed in response to treatment with 900 µM of 4-TBP, but not following MBEH
treatment (Fig. 5c).
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Fig. 5 Caspase-3 and PARP in MBEH and 4-TBP treated cells
Melanocytes were treated with 500 or 900 µM of 4-TBP or MBEH for 1 hour and
analyzed for (a) caspase-3 activity, (b) cleavage of caspase-3 and (c) PARP cleavage. (a)
Caspase-3 activity (nmoles/mg/hour) was quantified based on the amount of fluorescence
emitted upon cleavage of the substrate Ac-DEVD-AFC. Statistical significance at p<0.05
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was observed for caspase-3 activity after 900 µM treatment of 4-TBP over vehicle
treatment. (b) Cleavage of caspase-3 identified through western blotting revealed no
caspase-3 cleavage following MBEH treatment, whereas 4-TBP treatment does induce
cleavage of pro-caspase (32 kD) into active caspase (11 kD). (c) Treatment with 4-TBP
treatment induced cleavage of PARP (116 kD) into inactive PARP (89 kD), while MBEH
treatment did not induce PARP cleavage.

46
Analysis of necrotic changes
The morphological changes of cultured melanocytes in response to 4-TBP and
MBEH were studied by light microscopy. Melanocytes were treated with 250 µM of 4TBP and MBEH for 24 hours or with 900µM for 1 hour, and structural alterations were
observed. Representative Fig.ures are shown in Fig. 6a. Both 4-TBP and MBEH induced
cell detachment. With 4-TBP apoptotic changes such as perinuclear vaculorization,
dendrite retraction and membrane ruffling were observed as shown by representative
arrows. MBEH treated cells however, demonstrated no apparent signs of apoptosis.
Vehicle treated cells showed no significant morphological changes compared with
untreated control cells. Following this, the ultrastructural changes in response to 4-TBP
and MBEH exposure were examined by electron microscopy. Physiologic changes in
treated cells were most readily demonstrable at the 1mM concentration for 1 hour, as
shown in representative images of individual cells in Fig. 6b. An electron micrograph of
intact cells is shown for vehicle treatment alone. Exposure to 4-TBP produced defined
apoptotic features including formation of apoptotic bodies, cytoplasmic vaculorization,
blebbing of the plasma membrane and a condensed nucleus, while maintaining plasma
membrane integrity. MBEH treated cells revealed typical necrotic features such as
disruption of the plasma membrane and release of cellular contents. Even at 125 µM
treatment for 4 hours, similar ultrastructural features could be observed in response to
MBEH, but not to 4-TBP (not shown). Also, the release of HMGB1 in the supernatants
of melanocytes treated with 900 µM of 4-TBP or MBEH for 1 hour was analyzed through
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western blotting. As expected, HMGB1 was released upon MBEH treatment alone
further confirming the necrotic pathway (Fig. 6c).
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Fig. 6 Analysis of necrotic changes
a) Melanocytes Mf0632 P4 were treated with 250 µM of 4-TBP or MBEH for 24 hours,
or 900 µM 1 hour and morphological changes were observed using a light microscopy.
4-TBP treated cells demonstrate changes such as membrane blebbing (long arrows),
dendrite retraction (stars) and perinuclear vacuolarization (short arrows), MBEH
treatment cells show non-adherent cells (arrowheads), and dendrite retraction (stars). (b)
Morphological changes in melanocytes treated with 1mM 4-TBP or MBEH or vehicle
alone for 1 hour were evaluated by electron microscopy. Vehicle-treated cells show intact
plasma membranes (arrows) and nuclear membranes (asterisks). 4-TBP treatment
induced apoptotic changes including: cytoplasmic vacuolarization (filled arrowheads),
plasma membrane blebbing (open arrow heads), and formation of apoptotic bodies (carrot
symbol). MBEH treatment induced necrotic changes consisting of plasma membrane
(arrows) and cytoplasmic disintegration. Scale bars equal to 2 microns. (c) Western blot
analysis of melanocyte (Mf0930 P2) supernatant to detect HMGB1 after treatment with
900 µM of 4-TBP or MBEH for 1 hour. Release of HMGB1 was identified after MBEH
treatment alone. Serum albumin bands observed in the respective supernatants were
shown to demonstrate equal loading.
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Confocal analysis of DNA fragmentation in exposed skin
DNA fragmentation in treated explants was analyzed by TUNEL staining. Human
skin explants of 6mm in diameter were treated with 5µl of 250 mM of 4-TBP or MBEH
for 1 day. Control explants were treated with vehicle alone. Cryosections were
immunostained with APC-labeled anti-MART-1 (melanoma antigen recognized by T
cells-1), incorporating FITC-labeled nucleotides with the Klenow fragment of DNA
polymerase to free ends of fragmented DNA. Sections were counterstained with DAPI
(4’, 6-diamidino-2-phenylindole) to identify cell nuclei. Stained sections were analyzed
by confocal microscopy (Fig. 7). Similar to control samples, MBEH treated explants
demonstrated focal DNA fragmentation in the granular layer of the epidermis and in the
dermis, whereas no apoptotic signal was observed throughout the basal layer where
melanocytes are situated. Apoptotic melanocytes were observed in 4-TBP treated skin
with colocalization of TUNEL (in green) and MART-1 staining (red). 4-TBP treatment
induced DNA fragmentation in 80% of basal melanocytes within skin explants as
opposed to MBEH treatment where not a single apoptotic melanocyte was observed.
Note that at the high concentration of either agent used, keratinocyte apoptosis was
observed within 4-TBP treated explants only, further emphasizing the contrast between
both agents.
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Fig. 7 DNA fragmentation within MBEH or 4-TBP treated skin
Apoptosis was shown in confocal microscopic images of explant cultures exposed to 5µl
of 250 mM 4-TBP or MBEH for 24 hours. Vehicle treatment alone served as control.
Melanocytes immunostained with antibodies to MART-1 were shown in red and DNA
fragmentation was represented in green. Nuclear counterstaining by DAPI was observed
in blue. Colocalization of all three colors is visible in white. Vehicle and MBEH treated
skin sections lacked DNA fragmentation in the basal epithelial layer, whereas 4-TBP
treatment showed melanocytes expressing DNA fragmentation. Scale bar is equal to 20
microns.
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Role of pigmentation in MBEH-mediated death
A role for melanin in the toxicity induced by MBEH was identified by correlating
melanocyte viability after MBEH exposure to melanin levels observed in cultured
melanocytes. In Fig. 8a, a positive correlation between cellular melanin content and
viability following MBEH treatment was observed, with a correlation coefficient of 0.6.
By contrast, melanin content did not correlate with cell death mediated by 4-TBP. In Fig.
8b, expression levels of melanogenic enzymes tyrosinase, TRP-1 and TRP-2 are shown
for six melanocyte cultures arranged from left to right according to increasing viability in
presence of MBEH. Indeed, sensitivity to MBEH was not specifically associated with the
levels of expression of any of these melanogenic enzymes. Interestingly, whereas the
expression levels of tyrosinase and TRP-1 vary with melanin content, no such association
was demonstrated for TRP-2 suggesting that TRP-2 expression is of less importance for
melanization. Taken together, the data support a protective role of melanin in MBEHinduced cell death.
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Fig. 8 Role of pigmentation upon MBEH-mediated death
(a) Melanocytes were treated with 500 µM of 4-TBP or MBEH for 24 hours and cell
viability was quantified with MTT assays. Melanocyte viability was correlated with
baseline cellular melanin content. (b) The baseline expression levels of TRP-1, tyrosinase
and TRP-2 were quantified by FACS analysis. Expression levels of melanogenic
enzymes reported for individual melanocyte cultures were arranged according to
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increasing melanocyte viability upon MBEH exposure from left to right. The melanin
content of each melanocyte culture was reported in pg/cell underneath the culture name.
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Melanosomal marker analysis through intracellular staining
Relative changes in the expression of melanosomal proteins were identified in
melanocytes pre-treated with 4-TBP or MBEH versus treatment with vehicle alone. As
shown in Fig. 9, 4-TBP treated melanocytes expressed levels of TRP-1, tyrosinase and
TRP-2 reduced by 37%, 20% and 23%, respectively. MBEH-treated melanocytes
displayed an opposite trend with the levels of TRP-1, tyrosinase and TRP-2 increased by
13%, 67% and 81% over vehicle-treated cells, respectively.
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Fig. 9 Melanosomal marker analysis in cultured melanocytes
Melanocytes (Mf0639 P6) were treated with 250 μM of 4-TBP or monobenzyl ether of
hydroquinone (MBEH) for 72 hours. The cells were stained for expression of TRP-1,
TRP-2 and tyrosinase, and the expression levels were quantified by FACS analysis. (a)
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Histogram showing representative FACS staining for tyrosinase and (b) bar graph
indicating relative expression levels of tyrosinase-related protein-1 (TRP-1), tyrosinase
(TYR), and tyrosinase-related protein-2 (TRP-2) compared with vehicle-treated cells
which was set as 100%.
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Measurement of ROS generation
Melanocytes (Mf0639) were loaded with 25 μM of DCF, washed and then treated
with 900μM of 4-TBP or MBEH and followed over time for ROS generation. Emission
of green fluorescence at 530nm was quantified as amount of ROS generation over
various time points. 100μM of H202 was used as a positive control. Fig..10 shows a timedependent increase in free radical generation after 60 minutes and 30 minutes with 500
and 900 μM treatment of MBEH, respectively. 4-TBP treatment did not induce any free
radical generation. This indicates that free radical generation might be an upstream event
of necrotic melanocyte death upon MBEH treatment. Experiment was repeated thrice in
different melanocyte cultures and a representative experiment is shown in Fig.10.
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Fig. 10 Quantification of ROS generation in 4-TBP or MBEH treated melanocytes
Green fluorescence emitted by DCF was quantified as a measure of ROS generation in
melanocytes treated with 500 and 900 µM of 4-TBP or MBEH for 1 hour. MBEH
induced time- -dependent generation of free radicals both at 500 and 900µM, while no
ROS was detected upon 4-TBP treatment.
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Discussion
MBEH (10-20%) is used in dermatology clinics within the United States for
depigmentation treatment of patients with advanced vitiligo (157). The current studies are
the first to report on the underlying mechanism of depigmentation of human skin
mediated by MBEH. Viability assays demonstrated that similar to 4-TBP, MBEH induces
specific toxicity towards melanocytes as previously suggested by studies in mice (162,
172). At the same time, fibroblasts and melanocytes are equally sensitive to both agents,
suggesting that neither agent should be used for systemic administration, thus limiting
their use to topical application. Previous studies have reported that the mechanism of
melanocyte destruction by 4-TBP is through apoptosis (156). MBEH induced cell death
was therefore expected to follow a similar death pathway. Surprisingly, MBEH treatment
of cultured melanocytes induced unique morphological changes when compared with 4TBP treatment. While 4-TBP treatment induced perinuclear vacuolarization and
membrane ruffling, MBEH treatment induced disintegration of the cellular membrane
and release of cellular contents as observed by light microscopy. This suggested that the
mechanism of death initiated by MBEH may be different from that observed in response
to 4-TBP. Further studies confirmed that MBEH-induced cytotoxicity lacked classical
apoptotic hallmarks such as caspase-3 activity, cleavage of caspase-3 or PARP proteins,
exposure of phosphatidylserine and DNA fragmentation. Electron micrographs confirmed
the presence of necrotic changes including disruption of the plasma membrane and the
nuclear membrane. Furthermore, release of HMGB1 was observed following MBEH
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treatment alone, further emphasizing the same fact. Previous studies have demonstrated
that active PARP is required for the release of HMGB1 (173). This explains the lack of
HMGB1 release upon 4-TBP treatment, as 4-TBP induces cleavage and inactivation of
PARP.
During programmed apoptotic cell death, inflammation is a rare event, although
macrophage influx is required for a rapid clearance of apoptotic cells (168, 174). If
apoptotic cells are not phagocytized immediately, dying cells are cleared through a
necrosis-like mechanism referred to as secondary necrosis. Though secondary necrosis is
characterized by certain necrosis-like changes, nuclear fragmentation and chromatin
condensation are also observed (175). MBEH-mediated cytotoxicity does not induce
regulated nuclear fragmentation as seen by TUNEL staining, thus ruling out secondary
necrosis as the mechanism of cell death. Taking into account the structural,
morphological and biochemical changes observed, it was clearly demonstrated that
MBEH induces necrotic death in human melanocytes.
Correlative studies between melanin content and melanocyte sensitivity upon
MBEH exposure indicate that melanin acts as a protective agent against MBEH-induced
cell death. This implies that people with a darker complexion may benefit less from
MBEH depigmentation treatment. This is countered by the fact that recent studies
implicate tyrosinase as the enzyme mediating depigmentation in response to MBEH
(118). In this regard, MBEH appears to be converted into a quinone product upon
interaction with tyrosinase (118) . The accumulation of such quinone products may
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induce toxicity selectively in melanocytes (176). Alternatively, the possibility should be
considered that MBEH preferentially enters melanocytes as previously demonstrated for
4-hydroxy anisole in melanocyte-keratinocyte co-cultures (121). In either case, the
melanosome likely hosts the depigmenting compound, as further supported by the
protective effect of melanin against MBEH-induced cell death.
The upregulation of melanosomal markers through intracellular staining upon
MBEH treatment may in part explain the repigmentation observed in some patients
following depigmentation therapy (157), although a repopulation of depigmented skin by
melanocytes is likely required for such repigmentation to occur. Therefore, it is
postulated that a balance exists between the protective effects of melanin and the toxic
effects of quinone accumulation. Cell death occurs if quinone accumulation prevails. This
explains the lack of a direct association between the sensitivity to MBEH and the basal
levels of tyrosinase, TRP-1 or TRP-2, as the presence of melanin overshadows the toxic
effects of quinone products generated upon interaction with increasing levels of
melanosomal enzymes. This observation contrasts with the observed decrease in TRP-1
levels associated with increased viability upon 4-TBP exposure (Manga and Boissy,
2006). Overall, chemical exposure was accompanied by opposing consequences for the
expression of melanosomal enzymes both in vitro and ex vitro.
Oxidative stress is among possible causative factors in vitiligo (177). In this
respect, vitiligo patients demonstrate modified levels of superoxide dismutase and
catalase within the skin (178). Small nucleotide polymophisms (SNPs) were identified
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within the active site of catalase in some vitiligo patients. Modeling these SNPs
demonstrated that they can affect catalase activity and render patients more sensitive to
hydrogen peroxide (179). Also recently, the group of Schallreuter has identified
upregulated activity of xanthine dehydrogenase/xanthine oxidase, and increased
abundance of its metabolite allantoin in vitiligo epidermis (180). This can be ascribed to
previously observed increases in H2O2 in vitiligo skin reported by the same group. H2O2
also impacts epidermal acetylcholine esterase activity and conversion of tryptophan to 5HT (181). If serotonin synthesis is affected at a more systemic level, such findings can
even impact on depression and suicidal tendencies observed in vitiligo patients. We have
further reported significant increases in catechol-O-methyl transferase in vitiligo skin
(182). Taken together, there is evidence of oxidative stress in vitiligo skin, and analogous
to other diseases the presence of highly reactive oxygen radicals is likely to alter the
antigenic uptake of melanocytes (Chiang et al, 2008). Such changes can drive an immune
response to melanocytes. In this respect, it has been duly shown that minor modifications
in differentiation antigens otherwise avoided as self-molecules can render such molecules
immunogenic and drive autoimmune responses to unmodified variants of the same
molecules. This principle was used to develop a mouse model of autoimmune vitiligo
using human TRP-2 vaccines, for example. The vaccine elicits an immune response to
the human protein that expands to include shared epitopes. ROS generation upon MBEH
alone suggest that treatment with MBEH could be a potent activator of immune response
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since oxidized quinones are expected to react with proteins and peptides at a higher
affinity, thereby affecting their recognition by infiltrating T cells (183).
In conclusion, different mechanisms are involved in chemical depigmentation of
the skin by 4-TBP and MBEH. This leaves the intriguing question why one agent induces
apoptosis and the other necrosis of the same target cells. In part the explanation may be
found in the different side chains to either phenolic agent and resulting differences in
molecular structure potentially imposing differential reactivity towards melanocytes.
Both 4-TBP and MBEH are specifically cytotoxic to melanocytes upon topical
application with vastly different physiologic consequences that favor the application of
MBEH in a treatment setting. The data imply that MBEH is more likely to invoke an
inflammatory response and induce autoreactivity to melanosomal antigens which may
explain distant depigmentation away from the application site observed for this
compound (157). It may be possible to identify novel molecular derivatives or
combinatory treatments providing more rapid depigmentation of the skin. The current
studies provide an incentive for studies to unravel the possible impact of either agent on
immunologic responses to dying melanocytes, which can impact on the permanent
features of depigmentation.
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Fig. 11 Summary of Chapter 2
MBEH is specifically cytotoxic to melanocytes similar to 4-TBP. The mode of
melanocyte death mediated by MBEH is necrosis, while 4-TBP induces apoptotic
melanocyte death. In addition, MBEH generates ROS in melanocytes, not observed upon
4-TBP treatment. Finally presence of melanin reduces the toxic effect mediated by
MBEH and not 4-TBP. Thus the differential death mechanism mediated by bleaching
agents 4-TBP and MBEH could mediate a differential immune response in melanocytes.

CHAPTER III
IMMUNE ASPECTS OF DEPIGMENTATION TREATMENT
Abstract
Phenolic agents 4-tertiary butyl phenol and monobenzyl ether of hydroquinone
are preferentially cytotoxic to melanocytes and are known to induce vitiligo-like
pathogenesis in an occupational setting. Since they are toxic to melanocytes, the
therapeutic potential of these phenolic agents in melanoma treatment was explored by
quantifying the sensitivity of melanoma cells to either agent by in vitro cytotoxicity
assays. Initiation of an immune response mediated by 4-TBP or MBEH was studied in
treated explant cultures where the migration of Langerhans cells in to the dermal regions
was quantified by immunohistochemical analysis. Since explant cultures cannot be used
to study the influx of effector T cells from the lymph node further immunological studies
were performed in an in vivo setting. To assess the depigmenting potential of bleaching
agents in vivo, 4-TBP and MBEH were topically applied to C57BL/6 wild type as well as
k14-SCF transgenic, epidermally-pigmented mice. Further, the influx of T cells,
immigration of macrophages and cytokine expressions were measured in treated mouse
skin. MTT assays showed melanoma cells lines 888, 624.38, A375 and M14 were
relatively insensitive to either agent in comparison with melanocytes. Further, a lack of
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expression of melanocyte markers TRP-1 and tyrosinase corresponded with increased
melanoma cell line resistance to either agent, suggesting the involvement of melanosomal
enzymes in sensitizing melanoma cells to treatments. Melanoma cells being resistant to
4-TBP and MBEH in vitro, the therapeutic effects of these drugs are likely limited,
further supporting the need for a prophylactic approach to treatment for people with a
predisposition for familial melanoma. Since MBEH treatment induces necrotic
melanocytic death, an elevated level of immune response was expected in comparison
with 4-TBP treatment. A significant increase in the migration of Langerhans cells
towards the dermis only upon MBEH treatment suggested the selective elicitation of an
immune response. MBEH also induced significant skin depigmentation in both strains,
not observed upon 4-TBP treatment. Cytokine expression patterns in MBEH-treated skin
support activation of a Th1-mediated immune response corresponding to an influx of T
cells and macrophages. These data support that MBEH activate an immune response
while no immune reaction was observed upon 4-TBP treatment.
Introduction
Monobenzyl ether of hydroquinone or MBEH is currently in use as an FDA
approved agent to induce depigmentation in vitiligo patients (184). Depigmenting
qualities of the compound were first described following attempts to identify a cause for
skin depigmentation in an occupational setting. This led to the description of
‘occupational vitiligo’ as a separate disease category for patients undergoing gradual
depigmentation in a work related setting (154, 185). Several phenolic compounds have
been described that affect depigmentation either temporarily (such as hydroquinone) or in
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a permanent fashion (including MBEH) (184). As treatments for vitiligo are largely
ineffective, and patients with advanced depigmentation of their skin sometimes prefer an
even skin tone, MBEH is included as the active ingredient of monobenzone cream, used
to depigment the remainder of the skin over the course of several weeks to months (186).
The working mechanism of MBEH and other depigmenting agents is less well
understood. Permanent depigmentation of the skin observed in most patients does suggest
that the drug is capable of selectively eliminating melanocytes from the epidermis.
Recent data showing selective cytotoxicity of MBEH towards melanocytes and not
keratinocytes support this viewpoint (chapter 2) (187). Its selective action towards
melanocytes has been explained by structural homology to tyrosine, the natural substrate
for melanogenesis. When combined with the rate limiting enzyme for melanogenesis,
tyrosinase, MBEH is converted into a highly reactive quinone that is suggested to react
with surrounding enzymatic compounds within the confines of the melanosomal
organelle (115). As expression of melanosomal enzymes is restricted to cells of the
melanocyte lineage, the above sequence of events can explain a selective cytotoxic effect
of MBEH on melanocytes. It should be considered that different phenolic compounds can
follow markedly different depigmentation strategies. In this respect, whereas MBEH is
thought to bind tyrosinase, 4-tertiary butyl phenol appears to interact with TRP-1 (118,
163).
Quinone binding to melanosomal compounds occurs in a process described as
haptenization, whereby the hosting compound undergoes slight structural alterations
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(118). Melanosomal enzyme modification is significant as TRP-2, MART-1, gp100 and
tyrosinase itself are immunogenic molecules, and minor changes in amino acid
composition or even haptenization have been shown to alter their recognition by T cells
reactive with the native peptide (183). By increased affinity for the modified peptide,
immune tolerance can be broken and improved reactivity will likely ensue. This process
is significant for understanding the depigmentation process in vitiligo.
Upon studying the effects of MBEH exposure for melanocyte viability, it was
found that sensitivity to MBEH exposure is not directly correlated with the expression of
a single melanosomal compound. Rather, there was an inverse relationship noted for
sensitivity to MBEH and generation of melanin within the cell. More intensely pigmented
cells are thus increasingly resistant to the compound (chapter 2) (187). This can have
implications for the treatment of ethnic skin with MBEH.
Besides an understanding of the direct effects of bleaching phenols on pigmented
cells, any consequences for cell viability will indirectly affect immune responses to
follow. In this regard, the markedly different effects of MBEH and 4-TBP on
melanocytes manifest themselves in the induction of necrosis and apoptosis, respectively,
in exposed cells (187). Both death pathways are thought to have markedly different
consequences on dendritic cell activation and it is thus likely that 4-TBP and MBEH
exposures have markedly different kinetics of depigmentation in an in vivo setting.
The mechanism of action of bleaching phenols becomes particularly important
when considering the specificity for cells of the melanocytic lineage. Besides normal
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epidermal and ocular melanocytes, cells potentially sensitive to the effects of MBEH and
4-TBP can thus include melanoma cells. Systemic toxicity however limits the application
of bleaching phenols in a therapeutic setting. The toxicity of both MBEH and 4-TBP
towards fibroblasts, for example, is significant (chapter 2) (163, 187). To nevertheless
make use of the unique qualities of bleaching phenols towards the treatment of melanoma,
two supportive factors are considered here. First, eliminating melanocytes from the skin
will prevent precursor cells from converting to melanoma cells by malignant
transformation. Thus this process may be effective as a chemical alternative to elective
surgery for patients familial melanoma, or to prevent recurrences in patients following
surgical removal of a primary tumor. Second, cell death among a portion of melanocytes
in the skin may elicit an immune response that carries over to an effective anti-tumor
response by the recognition of antigens shared between melanocytes and melanoma cells
(153, 188-189). Familial melanoma is a condition affecting approximately 10% of
melanoma cases, or an estimated 6000 newly diagnosed patients per year in the United
States alone (190). If induction of vitiligo can spare patients from agonizing returning
visits to the dermatologist to check for newly arising dysplastic nevi, treatment with
bleaching phenols may be a more effective and permanent way to address familial
disease.
To study the potential of prophylactic treatment using bleaching phenols for
familial melanoma, it is necessary to first identify the in vivo effects of the agents under
study in an in vivo setting, in particular to address the anticipated involvement of an
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immune response. Here, the effects of bleaching agents 4-TBP and MBEH were studied
initially in normal human skin, in order to quantify Langerhans cell emigration in
response to either agent. Organotypic cultures of human skin are ideal for these studies,
as emigration can be studied without new influx of immune cells (170). Since Langerhans
cells migrate upon antigen specific stimulation, the same approach has been followed to
distinguish allergenic compounds from skin irritants (191-192). This same factor limits
the use of skin cultures to assess T cell influx, and these studies were executed in mouse
models instead. To this end, bleaching agents were applied to the skin of wildtype mice
as well as a transgenic model designed to express melanocytes in the epidermal
compartment of the skin. In the k14-SCF mouse, stem cell factor is expressed under the
k14 promoter within keratinocytes to support melanocyte maintenance within the skin
environment, which is important to follow topical application of the bleaching agents
(193). Depigmentation was quantified in both models and T cell influx, immigration of
macrophages and cytokine expressions were measured in the skin. To understand whether
these agents can be used to target melanoma cells, the sensitivity of human melanoma
cells were quantified by in vitro cytotoxic assays. Taken together, these data shed
important light on the prophylactic potential of bleaching agents for the treatment of
familial melanoma.
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Materials and Methods
Mouse models
Two strains of mice, C57BL/6J from Jackson Labs (Bar Harbor, ME) and k14SCF transgenic mice (193), were used in the depigmentation experiments. In the k14SCF mice, mouse stem cell factor is expressed under the k14 promoter which maintains
melanocytes within the epidermis, thus rendering k14-SCF mice a close mimic of human
skin. Group sizes were 5 per group for C57BL/6J mice and 4 per group for k14-SCF mice
unless stated otherwise. All experiments were approved by Loyola University Medical
Center's Institutional Animal Care and Use Committee.
Preparation of bleaching agents and treatment
4-TBP (Sigma-Aldrich, St Louis, MO) was prepared as a stock solution of 3M in
70% ethanol. MBEH (Sigma) was dissolved in 20% dimethyl sulfoxide (Sigma) and
mixed with 70% ethanol for a stock concentration of 3M. The use of a vehicle control
refers to the use of 20% dimethyl sulfoxide in 70% ethanol. The chemicals were stored as
a stock at -20˚C until further use. Before necessary treatments, chemicals were mixed
with Eucerin calming cream (Beierdorf, Wilton, CT) to a final concentration of 1M or
1.5M.
Mice were prepared for depigmentation treatment by biweekly ventral hair
removal with Nair (Church and Dwight Co., Princeton, NJ).

C57BL/6 mice were

topically treated with 100µl of 1.5 M 4-TBP or MBEH applied to a 3 cm2 area of Naired
skin on alternate days for 6 weeks. The k14-SCF mice were similarly treated with 100µl
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of 1M concentration of 4-TBP or MBEH for 14 weeks. Mice were anesthetized during
hair removal and bleaching phenol treatments using an isofluorane gas chamber
(Euthanex Corp , Plamer, PA).
Organotypic culture of treated human skin
Organotypic culture was performed as described previously (170). In brief, 4mm
biopsies were punched from otherwise discarded foreskin tissue obtained after routine
circumcision. Explants were cultured in DMEM containing 10% inactivated normal
human serum at the air–liquid interphase with epidermis facing up in 12-well transwell
plates with a 0.4 µM pore size (Corning, Teterboro, NJ). After topical treatment with 5 µl
of 250 mM of 4-TBP or MBEH daily for 3 days, explants were embedded in optimal
cutting temperature compound (OCT) (Sakura Finetek USA, Torrance, CA), snap-frozen
and maintained at -80 °C for future sectioning. All studies performed with human tissue
were carried out in adherence with the Declaration of Helsinki Principles and were
approved by the Institutional Review Board of the institution where circumcisions were
performed.
Cell culture
Mouse melanocyte cultures were initiated from untreated k14-SCF mice skin
samples. After euthanasia, mouse skin samples were homogenized O/N in an enzymatic
cocktail (thermolysin 0.05mg/ml, collagenase 1mg/ml, trypsin 0.1mg/ml, DNase
0.01mg/ml) prepared in DMEM (Media-Tech, Manassas, VA). Cells were cultured in
Ham's F-12 medium (Media-Tech, Herndon, VA) with 10% heat-inactivated fetal bovine
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serum (Gemini Bio-products, West Sacramento,CA), 2mM glutamine (Media Tech),
100IU/ml penicillin, 100µg/ml streptomycin 100µg/ml amphotericin (Media Tech),
0.1mM IBMX (Sigma), 10ng/ml 12-O-tetradecanoyl phorbol-13-acetate (Sigma), and
0.03% bovine pituitary extract

(InVitrogen).B16F10 mouse melanoma cells were

maintained in DMEM (Media-Tech) with 10% heat-inactivated fetal bovine serum
(Gemini Bio-products), 100IU/ml penicillin, 100µg/ml streptomycin and 100µg/ml
amphotericin (Media-Tech).
Evaluating depigmentation
Depigmentation was evaluated by flatbed scanning of the ventral side of the mice
under anesthesia, and subsequent image analysis using Adobe Photoshop software
(Adobe Systems Inc., San Jose, CA) as described previously (194). Depigmentation
experiments were repeated thrice and a representative experiment was shown. Briefly,
depigmentation is evaluated by quantifying mean luminosity of inverted images for the
treated area, comparing the data to untreated mice. Statistical analysis of data was
performed by comparing relevant groups by Student's T-test using Excel software.
Immunohistology
Biopsies of treated mouse skin, treated human skin explants, or mouse tumor
tissue were embedded in OCT compound (Sakura Finetek USA, Torrance, CA), snapfrozen on dry ice. Eight µm cryostat sections were fixed in cold acetone and stored at 20 °C until use.
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Human explant sections were stained with antibody CD207 to Langerin (mouse
monoclonal: Immunotech, Marselle, France). Vehicle application was used as a negative
control. Recruitment of Langerhans cells was evaluated in 3 human skin biopsies per
group. Mouse skin sections were stained with biotinylated hamster antibody 145-2C11 to
CD3ε antibody (Pharmingen, San Diego, CA, or goat T-16 ab to CD68 (Santa Cruz
Biotechnology Inc, Santa Cruz, CA). Peroxidase labeled anti-mouse or anti-goat antisera
or peroxidase labeled streptavidin (Southern Biotechnologies, Birmingham, Alabama)
was used in the second step and color was developed using aminoethyl carbazole (AEC)
as a substrate (Sigma) as described earlier (144). Quantifications were performed in 2
serial sections from tissues of 4 mice/group. Stained cells were counted within the
epidermis for CD3+T and Langerin + Langerhans cells to a depth of twice or four times
the epidermal thickness in the dermis to quantify Langerin + Langerhans cells and CD68+
macrophages respectively. Epidermal length or area was calculated using Adobe
Photoshop CS4 software (Adobe Systems Inc).
Cytotoxicity Assay
Cell viability was measured by MTT assays (Bioassay system, Hayward, CA)
according to manufacturer’s instructions. In brief, 20,000 cells/well were plated in
triplicate wells of a 96- well plate to attach overnight. Cells were either treated with
vehicle alone or with 250, 500 or 900µM of 4-TBP or MBEH for 24 hours. MTT reagent
(tetrazole) was added to the cells and incubated in a 37C humidified chamber for 4 hours.
Tetrazole is converted to formazan in mitochondria of living cells. The formazan crystals
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formed were solubilized in buffer and the wavelength was read in a reader at 562 nm
(BMG labtech inc, Durham, NC). Cell viability was calculated as a percentage of
absorbance of the samples relative to vehicle treated control.
Evaluating DC maturation
Bone marrow-derived monocytes were prepared by culturing murine bone
marrow cells using protocols modified from Boudreau et al (195). Briefly, bone marrow
cells were flushed aseptically from the femurs and tibia of mice. Monocytes were
enriched using the EasySep mouse monocyte enrichment kit (Vancouver, BC) according
to the manufacturer’s instructions. To generate DC, the monocytes were grown in RPMI
(Mediatech Inc., Manassas, VA) supplemented with 10% FBS and 100 U/ml penicillin,
100 µg/ml streptomycin, 50 ng/ml murine GM-CSF (Peprotech, Rocky Hill, NJ) and 12.5
ng/ml murine IL-4 (Peprotech). Cells were plated at 2x106 cells per 5 ml of media in
Teflon containers (Savillex, Minnetonka, MN) to prevent adherence. Half of the media
was replaced every other day for seven days. On day seven, 125 µM of 4-TBP, 63µM or
125 µM of MBEH, or 1µg/ml lipopolysaccharide (LPS) (Sigma) was added to the cells.
After 24 h, cells were gently spun and stained with Hamster anti-mouse CD11c, CD80,
CD83, CD86, and MHCII labeled with V450, APC, PE, PE-Cy and FITC fluorochromes
respectively (BD Biosciences, Sparks MD). Initial gating was performed on live nondebris singlets, with subsequent gating towards CD11c cells using FACS LSR-II
equipment (BD Biosciences).
Real time PCR
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Cytokine profiling was performed in treated mouse skin in remaining
subcutaneous tumor tissue. Sample sizes were 5 per group for skin samples and 3 for
remaining tumor tissue obtained from vehicle and 1.5M MBEH-treated animals. RNA
was isolated from tissue sections using TRIzol reagent (Invitrogen, Carlsbad, CA) and
further purified using an RNeasy mini kit (Qiagen, Valencia, CA). Two μg of RNA was
reverse-transcribed with superscript III (Invitrogen) and 10% of resultant cDNA was
included in the real time PCR reaction. Real time PCR was performed using Quantitect
SYBR green master mix and samples were run in triplicate and amplified at 95°C for 10
minutes, 95°C for 15 seconds, 55°C for 30S, 72°C for 30S for 50 cycles. Standard mouse
primer sets and probes for IFN, IL-2, IL12b, IL17a, TNFα, IL-10, IL-4, and GAPDH
were purchased from Qiagen. Relative fold change in gene expression was calculated
using the ΔΔ Ct method after normalizing with vehicle treatment (196-197). Experiments
were repeated thrice. Representative data from a single experiment is shown.
RESULTS
Evaluating sensitivity of melanoma cells to bleaching phenols
Viable melanoma cells (624.38, 888 and A375) and melanocytes were identified
using green fluorescent marker calcein AM after treatment with 900 μM of 4-TBP or
MBEH. A substantial reduction in viability was observed in melanocytes with both 4TBP and MBEH treatment, while no changes were observed in melanoma cells (Fig.
12a). Representative fluorescent images are shown in Fig.12a.

The sensitivity of

melanoma and melanocytes were then quantified using MTT assays after 250 and 500
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μM treatment of 4-TBP or MBEH for 24 hours. Both 4-TBP and MBEH induced >65%
of cell death in melanocytes, while melanoma cells maintained >60% viability upon
treatment (Fig.12b). To identify whether resistance of melanoma cells to bleaching agents
was due to loss of melanocyte markers, the basal level of melanocyte markers was
evaluated by intercellular staining of melanoma and pooled melanocyte cultures and
analyzed by FACS. Fig.12c indicates expression levels of tyrosinase, TRP-1 and TRP-2
corresponding to the relative sensitivity towards either agent.
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Fig. 12 Sensitivity of melanoma cells to 4-TBP and MBEH
a)Melanoma cultures exposed to 900 µM of 4-TBP or MBEH for 1 hour and treated with
Calcein AM to visualize live cells. b) Sensitivity of human melanoma cell lines A375,
M14 (amelanotic), 888, 624.38 (melanotic) was compared with melanocyte cultures
(pooled dark and light melanocytes) to 250 and 500 µM of 4-TBP or MBEH for 24 hours.
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Viability was measured by MTT assays. c) Basal melanocyte marker expression in
melanoma cells and melanocytes were compared with their respective viability upon 500
µM treatment with 4-TBP or MBEH for 24 hours. Results of studies comparing basal
marker expression with relative sensitivity suggest potential involvement of tyrosinase
and TRP-1 in sensitizing melanoma cells upon bleaching agent treatments.
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Eliciting immune responses by 4-TBP and MBEH in skin explants
Langerhans cell abundance and migration were monitored as a measure of the
elicitation phase of an immune response in human explant cultures treated with 250mM
of 4-TBP or MBEH for 3 days (Fig.13). Representative staining for each treatment is
shown in Fig.13a.. Although the total number of Langerin+ cells in the epidermis
remained constant (Fig.13b), agents 4-TBP and MBEH respectively induced a 2.4 and 2.9
fold increase in migration of Langerhans cells towards the basal layer of the epidermis in
comparison to vehicle treatment alone (p<0.05)(Fig.13c). In addition, MBEH and not 4TBP treatment caused a 2.0 fold increased migration into the dermis over control
treatment (p<0.01) (Fig.11d). These data support that the immune activation particularly
upon MBEH treatment.
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Fig.14 Eliciting immune responses by 4-TBP and MBEH in human skin explants
Explant skin cultures were treated with 250 mM of 4-TBP or MBEH for 3 days and
stained for the presence of Langerhans cells. Vehicle treatments alone served as controls.
(a) Representative image of Langerin staining for each treatment is shown. (b)
Quantification of total Langerhans cells in the epidermis (c) Quantification of Langerhans
cells in the basal layer represented as number of cells/mm epidermal length. (d)
Quantification of Langerhans cells in the reticular dermis expressed as number of
cells/mm2. Mean and SE were calculated and statistical significance was evaluated by
Students’t-test (n=3) for epidermal measurements and (n=4) for dermal measurements.
‘*’ indicates p<0.05. A 2.4- and 2.9-fold increase in migration of Langerhans cells
towards the basal layer of the epidermis was observed upon 4-TBP and MBEH treatment
respectively over control, while a 2.0-fold increase in migration of LC in to the dermis
over control was observed only upon MBEH treatment.

85
Effect of phenolic agents on dendritic cell maturation
Immature myeloid dendritic cells derived from bone marrow precursors were
treated with 63 or 125 μM of MBEH, 125 μM of 4-TBP for 24 hours. Cells stained for
activation markers were quantified in live CD11c positive cells (Fig. 14). While no
activation was observed upon 4-TBP treatment, 1.6-, 1.3-, 1.1- and 1.1- fold activation
for CD80, CD83, CD86 and MHCII respectively was observed upon MBEH treatment.
Such limited activation and maturation may contribute to the migratory behavior of DC
subsets in response to MBEH, but not 4TBP treatment.

86

Fig. 14 Effect of phenolic agents on dendritic cell maturation
Immature dendritic cells derived from bone marrow precursors were treated with 125μM
of 4-TBP, 63 μM or 125μM of MBEH for 24 hours. Live Cd11c+cells were then stained
for dendritic cell activation markers. Vehicle treatment served as a negative control while
LPS treatment served as a positive control. Experiments were repeated thrice and data
from a representative experiment are shown in Fig. 12. While no activation was observed
upon 4-TBP treatment, 1.6-, 1.3-, 1.1- and 1.1- fold activation for CD80, CD83, CD86
and MHCII respectively was observed upon MBEH treatment
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Topical application of bleaching agents in wild type mice
C57BL/6 mice were shaved biweekly to remove the ventral pelage and topically
treated with 100ul of 1.5 M MBEH or 4-TBP on alternating days for 6 weeks. Two weeks
after cessation of treatment, mice were scanned on a flat bed scanner and changes in
pigmentation of the pelage in the treatment area were measured by image analysis.
MBEH treatment induced a 20.5% reduction in pigmentation (p<0.0001), while 4-TBP
treatment induced 2.8% depigmentation (p<0.01) relative to vehicle treatment (Fig. 15b).
Scanned mice images were shown in Fig.15a. These data demonstrate that MBEH
penetrates the mouse skin at least to the follicular level.
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Fig. 15 Topical application of bleaching agents in wild type mice
C57BL/6 mice were shaved biweekly to remove ventral hair and topically treated with
100ul of 1.5M MBEH or 4-TBP on alternating days for 6 weeks. Two weeks after
cessation of treatment, mice were scanned on a flat bed scanner and changes in
depigmentation quantified. (a) Scanned images of C57BL/6 mice for each treatment
immediately following the cessation of the experiment. (b) Change in percent
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depigmentation with respect to the vehicle treatment. Mean and SE were calculated and
statistical significance was evaluated by the Student T test (n=5). ‘**’ indicates p<0.01:
‘***’ indicates p<0.0001. MBEH treatment induced a 20.5% reduction in pigmentation,
while 4-TBP treatment induced 2.8% depigmentation.
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Effect of bleaching agents on epidermally pigmented k14-SCF mice
Shaven ventral skin of k14-SCF mice was topically treated with 1M concentration
of 4-TBP or MBEH on alternating days for 14 weeks. Changes in the pigmentation levels
upon treatment with vehicle, 4-TBP or MBEH were shown among the regrown pelage of
k14-SCF mice in Fig.16a and 16b. The percent change in pigmentation was quantified
relative to vehicle treatment. 4-TBP treatment had no significant change in pigmentation
level in the regrown hair (Fig. 16b). However, MBEH caused 12.9% (p<0.0001)
depigmentation in hair when compared to vehicle treatment (Fig. 16b). This dataset
demonstrates that MBEH has a depigmenting effect on hair follicles in mice.
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Fig.16 Effect of bleaching agents on epidermally pigmented k14-SCF mice
Shaven ventral skin of k14-SCF mice was topically treated with 1M concentration of 4TBP or MBEH on alternating days for 14 weeks. Changes in pigmentation were
measured among regrown hair after the final treatment. (a) ) Scanned images of the k14SCF mice after regrowth of their hair. (b) Bar graphs represent percent depigmentation
levels of regrown hair with respect to vehicle treatment. Mean and SE were calculated
and statistical significance was evaluated by Student’s t-test (n=4). ‘***’ indicates
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p<0.0001. MBEH treatment caused 12.9% depigmentation in the hair, while no
depigmentation was observed upon 4-TBP treatment.
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Immune cell influx in response to MBEH versus 4-TBP
T cell and macrophage influx to the skin was quantified by staining for CD3+ and
CD68+ cells in epidermal and dermal skin regions respectively treated with 1M
concentration of either bleaching agents in k14-SCF mice for 14 weeks. MBEH treatment
induced a 2.0-fold increase in T cell infiltration (p<0.05), whereas 4-TBP treatment
resulted in a 0.5-fold reduction in the T-cell number when compared with control treated
skin (not significant) as shown in Fig. 17a. A similar trend was observed upon
macrophage infiltration to the dermal area of treated k14-SCF skin. MBEH treatment
induced a 2.4-fold increase in CD68+ cells (p<0.01), while 4-TBP treatment did not result
in a significant increase in macrophage infiltration compared with vehicle-treated skin
(Fig. 17b). This further supports the concept that MBEH activates an immune response
while no difference was observed upon 4-TBP treatment.
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Fig.17 Immune cell influx in response to MBEH versus 4-TBP
T cell and macrophage influx to the skin was quantified by staining for CD3+ and CD68+
cells in epidermal and dermal skin regions treated with 1M concentration of either
bleaching agents in k14-SCF mice for 14 weeks. (a) Influx of CD3+ cells in the
epidermal region of the mouse skin was quantified in 2 independent experiments and
expressed as number of stained cells/mm epidermal length. (n=6 for 4-TBP and MBEH
treatment; n=4 for vehicle treatment) (b) Influx of macrophages in to the dermal regions
of k14-SCF mice skin samples were quantified and expressed as the number of positive
cells/dermal area (mm2). Mean and SE were calculated and statistical significance was
evaluated by Student one-tailed T test. ‘*’ indicates p<0.05, ‘**’ indicates p<0.01.
MBEH treatment led to a 2 fold and 2.4 fold increase in the influx of CD3+ and CD68+
respectively, while no significant changes was observed upon 4-TBP treatment.
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Cytokine profiling in MBEH treated mouse skin
Cytokine environment was studied in frozen C57BL/6 mice skin after treatment
with vehicle or 1.5M MBEH for 6 weeks (Fig. 18). Increases in the relative transcript
levels of TNF-α, IFN-γ and IL-2 were observed at a 2.8, 2.4, and 2.4 fold, respectively
over vehicle treatment. Expression levels of IL-10, IL-4, IL-12 and IL-17 were not
altered, thus supporting a Th1 mediated immune response
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Fig. 18 Cytokine profiling in C57BL/6 mice skin treated with MBEH
Transcript levels of pro and anti-inflamatory cytokines evaluated by qRT-PCR in mice
skin samples treated with vehicle or 1.5 M MBEH for 6 weeks. Relative fold change in
the expression levels are shown upon normalization with vehicle treatment. Mean and
standard deviation were calculated from 3 replicates. Experiments were repeated thrice
and data from a representative experiment are shown. A Th1 mediated immune response
was observed upon MBEH treatment.
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Discussion
Vitiligo patients with advanced disease can opt for depigmentation therapy,
wherein topical application of bleaching agents is used to remove any remaining
pigmentation (184). The data presented here demonstrate that depigmentation in response
to MBEH can be reproduced in an in vivo mouse model. In accordance with our earlier
studies, the increased sensitivity of melanocytes to MBEH as compared to 4-TBP in vitro
(187) is accompanied by actual greater treatment efficacy in vivo. Contrary to expectation,
depigmentation of the pelage occurred more readily than depigmentation of the skin. This
may in part be a consequence of the densely populated and heavily melanized epidermis
of k14-SCF mice, as we have previously reported that melanin may protect against the
cytotoxic effects of MBEH (187).
Such data are of particular importance as the elimination of melanocytes from the
skin and hair follicles can theoretically serve as an alternative to ‘elective surgery’
offered for patient with mutations in tumor-associated genes (142, 198). For example,
such elective surgery is offered to patients with mutations in BRCA-1 or BRCA-2 where
the odds of developing breast- or ovarian cancer can increase from ~1% to virtually
100% (198). As preventive surgery is out of the question for familial melanoma patients,
the concept of chemoprevention proposed here can offer a much needed alternative for
patients with mutations in INK4a/ARF or CDK4 genes (14, 199). This idea is further
strengthened by the fact that melanoma cells are significantly resistant to either agent in
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comparison with melanocytes, thus making them potential chemopreventive agents for
familial melanoma.
As we have previously established, sensitivity to MBEH is specific for
melanocytes in the epidermis, but other cell types can display similar sensitivity to both
MBEH and 4-TBP, including fibroblasts (187). This precludes the use of bleaching
phenols in systemic applications, which is desirable in a therapeutic setting for melanoma.
Indeed, several authors have suggested the use of bleaching agents in the treatment of
melanoma(117).
It is an intriguing concept that bleaching agents can serve as a prodrug to be
selectively converted by enzymes uniquely expressed by melanocytes and melanoma
cells to generate toxic quinones. In fact, it has been proposed that resulting quinones may
in turn convert molecules in close proximity into increasingly immunogenic moieties
according to the ‘haptenization theory’ (115, 118). In this regard, the accelerated
depigmentation in response to MBEH in the order of magnitude observed here further
suggests that part of the depigmentation effects observed in vivo may actually be indirect.
We postulate that the necrotic pathway of cell death induced by MBEH as opposed to
apoptosis following exposure to 4-TBP may differentially affect processing and
presentation of melanocyte antigens and selectively lead to an immune response after
MBEH exposure (167-168, 187). Indeed, the data presented here strongly support
elicitation of an immune response in response to MBEH that is not found after 4-TBP
application. First, we observed Langerhans cell emigration from the epidermis of human
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skin in response to MBEH, whereas after 4-TBP application these cells were merely
found in basal position, thus remaining within the epidermis. It is likely that antigens
processed by intra-epidermal Langerhans cells will not be presented to T cells in draining
lymph nodes, thus preventing an influx of T cells to the skin. Such investigations required
moving from ‘ex vivo’ model in human tissue to ‘in vivo’ studies by engaging C57BL/6
or k14-SCF mice with epidermal melanocytes. In these in vivo studies, it was observed
that both macrophages and T cells primarily driven by Th1 cytokines infiltrate the skin in
response to MBEH, but not 4-TBP. A combination of infiltrating macrophages and T
cells is similarly observed in vitiligo and other auto immune disease and this combined
effect might be responsible for the removal of target cells under stress (158, 200-201).
Thus, the data presented here demonstrate that MBEH targets the melanocytes as
well activate a Th1 mediated immune response, thus acting as a potential agent for
preventive treatment for people with increased predisposition towards melanoma
development.
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Topical application of MBEH induces significant depigmentation in mouse models.
Further, application of MBEH and not 4-TBP cause emigration of Langerhans cell in
human skin and a Th1 mediated cytokine environment accompanied by an infiltration of
macrophages and T cells in mice skin.

CHAPTER IV
IN VIVO ASSESSMENT OF ANTI-TUMOR POTENTIAL OF MBEH

Abstract
Ideally, a familial melanoma mouse model to be used for studying the chemo
preventive effects of topically applied bleaching agents should have melanocytes in the
epidermis with genetic alterations that predispose them to malignant transformation.
However, in wild type mice, melanocytes are located strictly in hair follicles and the
animals lack epidermal pigmentation. Here an attempt was made to generate a suitable
mouse model for our studies, reflecting the chemo preventive potential of bleaching
agents for familial melanoma treatment. This can be achieved by crossing mice with
expression of activated H-RAS G12V (encoded on Y chromosome) driven by a tyrosinase
promoter on an Ink4a/Arf deficient background, and k14-SCF transgenic mice with
epidermal pigmentation in their skin due to transgenic expression of stem cell factor
(SCF) under the keratin 14 promoter. Tumors generated among pigmented, male
Ink4a/Arf -/- offspring were assessed for the presence of melanoma markers by FACS,
immunohistochemistry and Western blot techniques. Generation of non pigmented
cutaneous tumors among male offspring of the H-RAS G12V Ink4a/ARF -/- k14-SCF mice
suggested the absence of melanoma tumors. Indeed, tumors developing in parental male
H-RAS

G12V

Ink4a/ARF -/- mice similarly lacked expression of melanoma markers
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suggesting that activated RAS expression may not be driven by the tyrosinase promoter.
Thus, the tumor preventive effect of bleaching agent MBEH was instead identified by
pretreating k14-SCF mice and challenging them with B16 melanoma tumors. Pre
treatment of k14-SCF mice by MBEH significantly retarded tumor growth in mice
challenged with B16 melanoma cells, despite a clear insensitivity of human and mouse
melanoma cells to MBEH induced cytotoxicity. An abundance of cytotoxic T cells
accompanied by an increased expression of Th1 and Th17 cytokines observed in
remaining tumor tissues further emphasize immune mediated retardation of melanoma
growth. This protective immune effect is likely due to generation of antigenic substrate
by dying epidermal melanocytes. These data support the use of MBEH as a prophylactic
treatment for melanoma.
Introduction
Challenging wild type mice with B16 melanoma cells is the most widely used in
vivo model system to study the efficacy of proposed treatments for melanoma.
Identification of numerous genetic abnormalities in melanoma patients and a better
understanding of signaling mechanisms involved in melanoma genesis, led to the
development of several spontaneous melanoma mouse models to study the involvement
of the genes products of interest. Initial observations by Kamb et al that the CDKN2A
gene was either mutated, hyper methylated or deleted in more than 75% of human
melanoma cell lines led to the development of knockout mouse models for p16Ink4a and
p14Arf (6). Surprisingly, complete knockout of Ink4a/Arf led to spontaneous tumors other
than melanomas (32). However, approximately 50% of mice with complete loss of Ink4a
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but with one copy of Arf generated melanomas upon UV or DMBA exposure (202).
These results suggest that loss of Ink4a is essential for

tumorigenesis. However,

maintaining Arf in the heterozygous form might drive melanoma formation upon
carcinogen exposure. However, it is not clear how maintaining a single copy of Arf
would help in melanoma formation since Arf was shown to be present in the melanomas
after carcinogen exposure.(202).
As a variant to this model, Dr Chin and colleagues have since generated Ink4a/Arf
knockout mice expressing activated HRAS under the tyrosinase promoter (203). It should
be noted that the Tyr:HRAS transgene is present on the Y chromosome thus rendering
only males susceptible to melanoma. These mice are generated on an unpigmented
(albino) background due to a common nonsense mutation truncating the tyrosinase
protein. In the absence of external stimuli these mice develop unpigmented tumors in
approximately 16-20 weeks
Since our primary interest is to understand the effects of topical depimentation, it
is important to note that in the mouse, melanocytes are found in hair follicles rather than
in the epidermis (204). Mouse melanocytes can be re-directed to the epidermis during
development by epidermal expression of growth factors that support the maintenance of
melanocytes within this compartment. Existing models with epidermal melanocytes
include HGF and SCF transgenic mice. HGF transgenic mice were generated on an
albino background where mice do not express functional tyrosinase, and resulting
melanocytes are detected both in the dermis and in the epidermis (205). This model was

105
previously crossed with the Ink4a/ARF -/- model, and resulting mice have been
instrumental in demonstrating a link between melanoma genesis and UV exposure in the
absence of melanin (206). To study the chemopreventive effects of topical depigmenting
agents to familial melanoma, the expression of functional tyrosinase by melanocytes is
essential to recapitulate the conversion of bleaching phenol substrate into cytotoxic
quinones by tyrosinase exclusively in melanocytes (155). Pigmented, tyrosinase
expressing melanocytes are also a source of tyrosinase-derived antigenic peptides that
can enhance anti-tumor immunity (207). Mice that express membrane bound but not
secretory SCF under the k14 promoter carry melanocytes in the epidermis in the absence
of mast cell hyperproliferation (193).
In this chapter, attempts are described to generate the optimal model for testing
the prophylactic potential of topical bleaching treatment for familial melanoma. Initially,
the spontaneous cutaneous tumors among males mouse model (SCAM) mice model was
generated by crossing Tyr(Y) -HRAS Ink4a/Arf-/- Tg mice with the k14- SCF transgenic
model to generate mice that would ultimately develop pigmented melanoma in the
epidermal compartment.
In previous chapters, it was demonstrated that 4-TBP and MBEH are toxic to
melanocytes in comparison with keratinocytes (chapter2). In addition, 4-TBP and MBEH
are shown to activate apoptotic and necrotic death of melanocytes (chapter 2). Since the
mode of cell death plays an important role in the resultant immune response, it was
hypothesized that MBEH might activate an immune response. Ex vivo studies in treated

106
explants clearly indicated that MBEH might activate an immune response as it mediated
emigration of Langerhans cells from the epidermis (chapter 3). In addition, MBEH was
shown to induce potent depigmenting effects in C57BL/6 and k14SCF Tg mice. Finally,
the topical application of MBEH

in mice led to increased production of pro

inflammatory cytokines and increased skin infiltration by T cells and macrophages
(chapter 3). Thus, MBEH was identified as a potential candidate that can activate a twotierd response- removing the melanocytes and activating an immune response.
In this chapter, the anti-tumor immune response mediated by MBEH is described by
assessing the sensitivity of B16 melanoma cells to the cytotoxic effects of MBEH first,
followed by pre-treating k14-SCF mice and challenging them with melanoma cells
subcutaneously. Immune monitoring is performed on remaining tumors in pretreated and
untreated mice, both by qRT-PCR to quantify cytokine transcripts and indentify the type
of ongoing immune response, and by immunohistology to evaluate cytotoxic T cell
infiltration.
Materials and methods
Preparation of bleaching agents for in vivo treatment
4-TBP was prepared as a stock solution of 3M in 70% ethanol. MBEH was
dissolved in 20% dimethyl sulfoxide (Sigma, ST Louis, Mo ) and mixed with 70%
ethanol for a stock concentration of 3M. The use of a vehicle control refers to the use of
20% dimethyl sulfoxide in 70% ethanol. The chemicals were stored as a stock at -20˚C
until further use. Before necessary treatments chemicals were mixed with Eucerin
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calming cream (Beierdorf, Wilton, CT) to a final concentration of 1 or 1.5M with a
corresponding weight of 20 or 30 mg per 100μl respectively for MBEH, 15 and 20 mg
per 100μl respectively for 4-TBP.
Generation of SCAM model
The spontaneous cutaneous tumors among males mouse model (SCAM) was
generated by crossing k14-SCF mice (193) and Tyr H- Ras
Ink4a/Arf-/- mice (199). For convenience, Tyr H- Ras

G12V

G12V

(only in males)

(only in males) Ink4a/Arf-/-

mice will henceforth be referred as (1) and k14- SCF transgenic mice as (2).
Step 1
Since the constitutive active RAS is present only in the males of (1), males from
(1) were crossed with females from (2). The phenotypes for both mouse strains are listed
below in Table1. The offspring from this cross are 100% heterozygous for the Ink4a/Arf
deletion and k14-SCF pigmentation, with all males expected to express active RAS under
the tyrosinase promoter.
Table 1: Parental strains used

Y‐TYR RAS Ink4a/Arf ‐/‐
Ink4a/Arf (‐/‐) (aa)

K14‐SCF mice
Ink4a/Arf (+/+) (AA)

x y

Tyr‐RAS (‐/+) (b B )
Tyr‐RAS (‐/‐) (bb)
K14‐SCF (‐/‐) (cc)
K14‐SCF (+/+) (CC)
Wild type tyrosinase (‐/‐) (dd) Wild type tyrosinase (+/+) (DD)
Table 1: The Ink4a/Arf -/- mice have complete loss of Ink4a/Arf gene (aa) and have
active RAS under Y chromosome (bxBy), these mice also have mutated non functional
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tyrosinase gene (cc). The k14-SCF mice have wild type Ink4a/Arf (AA) and tyrosinase
genes (DD), with an SCF transgene under the k14 promoter (CC).
Step-2The F1 generation (AabxbxCcDd-female) was backcrossed with a male parent
(aabxByccdd) and vice versa. This backcross helped to generate homozygous knockouts
of Ink4a/Arf. Among the offspring, 16 possible outcomes can be obtained of which 12
were excluded by visual screening as they are either albino or do not express melanocytes
in the epidermis. The remaining genotypes were heterozygous for pigmentation and
epidermal melanocytes with all males exclusively expressing activated RAS

AabxbxCcDd

Punnett square-Back cross
(female offspring) X aaBybxccdd (male parent)

Phenotype of interest from backcross:
aa - INK4a/ARF homozygous
Bybx -Constitutive active RAS only in males
Cc- k -14 SCF heterozygous
Dd- wild type Tyrosinase.
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Table 2: Back cross of female
Female offspring/male aBycd
Parental
parent strain

abxcd

AbxCd

AaBybxCcDd (male)

AabxbxCcDd (female)

AbxCd

AaBybxCcdd (albino)

AabxbxccDd (albino)

AbxcD

AaBybxccDd (no-pig)

Aabxbxccdd (no-pig)

Abxcd

AaBybxccdd (both)

Aabxbxccdd (both)

abxCD

aaBybxCcDd (male)

aabxbxCcDd (female)

abxCd

aaBybxCcdd (albino)

aabxbxCcdd (albino)

abxcD

aaBybxccDd (no-pig)

aabxbxccDd (no-pig)

abxcd

aaBybxccdd (albino)

Aabxbxccdd (albino)

Table 2: Punnett square for the backcross between the female offspring and male parent.
The highlighted offspring were included in the next step.
Homozygous loss of the Ink4a/Arf gene was assessed by PCR from the DNA obtained
from the tail snips of selected male and female mice. Since the neomycin cassette was
used as a selection marker for the knockout of Ink4a/Arf gene, presence of neomycin and
absence of the Ink4a/Arf gene both confirmed the loss of Ink4a/Arf. In addition, the
presence of human RAS observed among the male offspring was used to confirm the
integration of the RAS transgene into the Y chromosome
Step 3
Ink4a/Arf-/- and RAS positive males were crossed with Ink4a/Arf-/- RAS negative
females, both with epidermal pigmentation. Male offspring from this cross were observed
for the development of cutaneous melanoma in about 17-18 weeks. Since the albino Tyr
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H-Ras G12V (in Y chromosome) Ink4a/Arf-/- mice was generated on an agouti background,
the F1 generation has an agouti coat color.
Genotyping
DNA was isolated from the tail snips of the desired mice offspring for genotyping.
The tail snips were incubated overnight at room temperature in tail salt buffer consisting
of 1% SDS, 5mM EDTA, 10mM Tris (pH 8.0), 100mM NaCl, 200ug/ml of fresh
proteinase K (Sigma, StLouis). Degraded protein was then precipitated by incubating at
40C with the tail salts made up of 4.21 M NaCl, 0.63 M KCL, 10mM Tris (pH 8.0). The
supernatant was mixed with 80% alcohol to precipitate the DNA. The DNA was
resuspended in Tris EDTA buffer. Desired DNA segments were amplified in the presence
of 50 mM MgCl2, 10mM of dNTPs, 2.5 μl of 10X PCR buffer (Fermentas, Maryland),
0.5 μl Taq Polymerase (Fermentas, Maryland) and 20 μM of each primer. PCR
amplification of target genes was performed at [950C 20 seconds followed by 580C 30
seconds and 720C 1minute] 40 X. Amplification was completed by incubation at 720C 10
minutes. The GAPDH primers and Ink4a/ARF primers used were derived from work
published by Chin et al (199) while human RAS primers were published by Scherl et al
(208) as shown in the table below.
To verify whether RAS is expressed under the tyrosinase promoter, forward
primers were designed in the -270 to-80bp region of the tyrosinase promoter supposedly
included in the original construct. This 270bp sequence 5’ to the tyrosinase gene is shown
to be necessary and sufficient to maintain cell type-specific and developmentally
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regulated expression of the tyrosinase gene (209). DNA from the tail of male Ink4a/Arf
mice was amplified using PCR master mix (Fermentas) with an upstream primer binding
within the tyrosinase promoter and a downstream primer to specifically amplify human
Harvey RAS and not endogenous mouse RAS. Additional primers were designed to
amplify human RAS and mouse tyrosinase as positive controls. Primers used are listed in
the table.
Table 3 Primers used for genotyping in the generation/validation of SCAM model
Neo-F

TGCTCCTGCCGAGAAAGTATCCATCATGGC

Neo-R

CGCCAAGCTCTTCAGCAATATCACGGGTAG

Ink4a-2F

GTGATGATGATGGGCAACGTTC

Ink4a-2R

GGGCGTGCTTGAGCTGAAGC

Ink4a-3F

AGGGCCCTGGAACTTCGCGGC

Ink4a-3R

GCTAGACACGCTAGCATCGC

GAPDH-F

ACCACAGTCCATGCCATCAC

GAPDH-R

TCCACCACCCTGTTGCTGTA

H- RAS-F

CAGGCCCCTGAGGAGCGATG

H- RAS-R

ATGTACTGGTCCCGCATGGCG

m TYR-F

CAATTTAGTTACCTCACTATGGGC

m TYR-R

GCCCATAGTGAGGTAACTAAATTG

TYR- PRO-F1

TGTTTCATGACCTTTATTCATAAG

TYR- PRO-F2

CAATTTAGTTACCTCACTATGGGC

H-RAS-R2

GCTGGATGGTCAGCGCACTCTTG

H-RAS-R1

CTGTGATGCTGAATCGGGGGTG

Table 3 Primers used for genotyping in the generation/validation of SCAM model
The Ink4a/Arf primers were designed in exons 2 and 3 of the CDKN2 gene, represented
as Ink4a 2 and 3 respectively. The primers designed to amplify Human Harvey RAS,
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neomycin, the tyrosinase promoter and GAPDH are represented as H-RAS, TYR-PRO,
GAPDH respectively. The primer combinations and amplification length are provided in
the table below
Table 4: Estimated product length for primers combinations
Primer combination

Amplification length

Neo F+Neo-R

380

Ink4a-2F+2R

339

Ink4a 3F+3R

104

GAPDH F+R

425

H-RAS F+R

500

m-TYR PRO F+R

132

TYR- PRO-F1+H-Ras-R2

1368

TYR-2F+H-RAS-R1

658

TYR-PRO-1F+H-RAS-R1

774

Cell culture
Mouse melanocyte cultures were initiated from untreated k14-SCF mice skin
samples. After euthanasia mouse skin samples were homogenized O/N in an enzymatic
cocktail (thermolysin 0.05mg/ml, collagenase 1mg/ml, trypsin 0.1mg/ml, DNase
0.01mg/ml) (Roche, Indiana) prepared in DMEM (Media-Tech, Manassas, VA). Cells
were cultured in Ham's F-12 medium (Media-Tech, Herndon, VA) with 10% heatinactivated fetal bovine serum (Gemini Bio-products, West Sacramento,CA), 2mM
glutamine (Media Tech), 100IU/ml penicillin, 100µg/ml streptomycin 100µg/ml
amphotericin (Media Tech), 0.1mM IBMX (Sigma), 10ng/ml 12-O-tetradecanoyl
phorbol-13-acetate (Sigma), and 0.03% bovine pituitary extract (InVitrogen).
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B16F10 mouse melanoma cells were maintained in DMEM (Media-Tech) with 10%
heat-inactivated fetal bovine serum (Gemini Bio-products), 100IU/ml penicillin,
100µg/ml streptomycin and 100µg/ml amphotericin (Media Tech).
The tumors isolated from male Tyr HRAS Ink4a/Arf -/- and SCAM mice were directly
plated or digested in a cocktail of thermolysin, DNase, collagenase and trypsin overnight
and plated in media containing DMEM (Media-Tech) with 10% heat-inactivated fetal
bovine serum (Gemini Bio-products), 100IU/ml penicillin, 100µg/ml streptomycin and
100µg/ml amphotericin (Media Tech).
Intracellular staining
Mouse melanocytes and tumor cells from SCAM mice were fixed in 2% paraformaldehyde and permeabilized using saponin. The tumor cells and mouse melanocytes
were stained with a cocktail of mouse monoclonal antibodies Ta99 to TRP-1 (Covance,
Dedham, MA), T311 to tyrosinase (Neomarkers, Fremont, MA), M2-9E3 to MART-1
(Covance), HMB45 to gp100 (DAKO) at 40C for 1 hour. Biotinylated rabbit anti mouse
immunoglobins were as used as secondary antisera (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) followed by PE or APC labeled streptavidin. Flourescence data were
acquired with a BD FACScanto flow cytometer (Becton Dickinson) and analyzed with
Flowjo software (Treestar).
Western Blots
Proteins isolated from B16F10 melanoma cells, SCAM tumor cells, mouse kidney
cells and Tyr HRAS Ink4a/Arf-/- mice tumor cells were electrophoresed in a 10%
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polyacrylamide gel and were transferred to a PVDF membrane (Millipore, Billerica, MA).
The blots were incubated with a mouse monoclonal antibody Ta99 to TRP-1 (Covance,
Dedham, MA). Peroxidase labeled, isotype specific goat antimouse serum was used in
the second step. The red color was developed using aminoethyl carbazole as substrate
(Sigma, St Louis).
Polymerase chain reaction
RNA from SCAM tumor cells and mouse melanocytes was isolated using TRIzol
and was reverse-transcribed with superscript III (Invitrogen,CA). One μg of cDNA was
amplified in presence of 50 mM MgCl2, 10mM of dNTP, 2.5 μl of 10X PCR buffer
(Fermentas, Maryland), 0.5 μl Taq Polymerase (Fermentas, Maryland) and 20 μM of
each primer. PCR amplification of target genes was performed at [950C 20 seconds]
followed by [580C 30 seconds, and 720C 1 minute] 40 X. The reaction was completed at
720C for 10 minutes. The primers used are stated below

Mouse gp100 F
Mouse gp100 R
mTRP-2 F
mTRP-2 R

ATGGGTGTCCAGAGAAGGAGCTTCCTTCCC
TCAGACCTGCTGTCCACTGAGGAGCGGGCT
ATGGGCCTTGTGGGATGGGGGCTTC
CTAGGCTTCCTCCGTGTATCTCTTG

Table 5: Primers used to identify SACM tumors
Primers used to characterize the SCAM tumors for the presence of melanoma markers.
Tumor challenge
The k14-SCF mice were treated with 1.5M of MBEH or vehicle for 3 weeks after
removing the pelage by application of Nair Church and Dwight Co., Princeton, NJ. A
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100l volume of 5x105 B16F10 melanoma cells in PBS was injected subcutaneously in
the right flank of MBEH treated and control mice. Tumor volume was recorded daily
from day 10 onwards using calipers. Data were pooled from two independent
experiments for a total of 8 vehicle treated and 10 MBEH treated animals. Statistical
significance of differences among treatment groups was evaluated using Student’s t- test.
Processing of tumor samples
Tumors biopsies from SCAM mice or B16 challenged k14-SCF mice were frozen
in OCT and stored at -80oC. SCAM mouse tumors were also digested in part in a cocktail
of thermolysin, DNase, collagenase and trypsin overnight to obtain single cell suspension
to be analyzed for the presence of melanoma markers through FACS and
immunohistochemistry.
Real time PCR
Cytokine profiling was performed in remaining subcutaneous tumor tissue from
B16 challenged mice. Sample sizes were 3 per group for remaining tumor tissue obtained
from vehicle and 1.5M MBEH treated animals. RNA was isolated from tissue sections
using TRIzol reagent and further purified using an RNeasy mini kit. Two μg of RNA was
reverse-transcribed with superscript III and 10% of resultant cDNA was included in the
real time PCR reaction. Real time PCR was performed using Quantitect SYBR green
master mix and samples were run in triplicate and amplified at 95°C for 10 minutes,
[95°C for 15 seconds, 55°C for 30S, 72°C for 30S for 50 cycles]. Standard mouse primer
sets and probes for IFN, IL-2, IL12b, IL17a, TNFα, IL-10, IL-4, GAPDH and CD3 were
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purchased from Qiagen (location). Relative fold change in gene expression was
calculated using the ΔΔ Ct method after normalizing with vehicle treatment (196).
Experiments were repeated twice with tumor samples. Representative data from a single
experiment are shown.
Immunohistology
SCAM tumor cells, B16 melanoma cells, and MOVAS cells (mouse smooth
muscle cells) (American Type Culture Collection (ATCC), VA) were plated in gelatin
coated chamber slides (Fisher Scientific, city, PA) to adhere overnight. Cells were fixed
in cold acetone for 10 minutes (Fisher). Fixed cells were stained with monoclonal
antibody Ta99 to TRP-1(Covance, Dedham, MA), and monoclonal antibody HMB45 to
gp100 (Dako, Carpinteria, CA ) for 1 hour. Individual alkaline phosphatase labeled or
peroxidase labeled isotype specific goat anti mouse antibodies were used as secondary
sera. The red color for TRP-1 and blue color to HMB45 was developed using aminoethyl
carbazole (Sigma) or fast blue BB (Sigma) as substrates. Images were captured by an
Olympus BX41 bright field microscope (Olympus, Center Valley, PA).
Tissues from 3 remaining tumor/group were engaged in the evaluation of infiltrating
CD8+T cells. Tumor sections were stained with biotinylated 53-6.7 rat antibody to CD8a
(Biolegend, San Diego, CA). Anti-rat alexa flour 568 (Invitrogen, Carlsbad, CA) was
used as a secondary antibody. Images were captured by an Olympus fluorescence
microscope (Olympus, Center Valley, PA
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Results
Genotyping of F2 generation for loss of Ink4a/Arf gene
Homozygous loss of the Ink4a/Arf gene in the F2 generation after backcross with
Tyr H RAS Ink4a/Arf-/- mice was assessed by PCR from the DNA obtained from the tail
snips of selected male and female mice. Since the neomycin cassette was used as a
selection marker for knockout of the Ink4a/Arf gene, the presence of neomycin and the
absence of the Ink4a/Arf gene both confirmed the loss of Ink4a/Arf. In addition, the
presence of human RAS was observed only in the male offspring confirming the
integration of RAS transgene in the Y chromosome as shown in Fig 20.
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Fig.20 Genotyping of SCAM mice
Genotyping of SCAM males and females for the loss of Ink4a/ARF and presence of
human RAS . N represents the selection marker neomycin, I-2 represent Ink4a/ARF gene
amplified with the primer designed for exon-2, I-3 represent Ink4a/ARF gene amplified
with the primer designed for exon-3. R represent human RAS gene and G represent
GAPDH, which serves as loading control. The bands of correct size are noted by
rectangular boxes. Representative experiment of screening performed on more than 20
mice
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Tumors in SCAM model
The SCAM male mice did generate tumors around 17-18 weeks, however they
were not pigmented suggesting that they might be non- melanoma tumors. A
representative male mouse displaying a cutaneous tumor is shown in Fig.21.
Validation of SCAM model
The tumor cells dissected from the male SCAM mice were digested in the enzyme
cocktail to obtain single cell suspensions. Isolated tumor cells were analyzed for the
expression of melanocyte markers both at RNA and protein level
a) FACS analysis of melanoma markers in SCAM tumor cells
Expression of melanoma associated antigens (MAA) was assessed by staining
with anti-TRP-1, anti-tyrosinase, anti-TRP-2, anti-gp100 and anti-MART-1 antibodies
and subsequent FACS analysis. Tumor cells from SCAM mice did not express the
melanoma associated antigens seen in mouse melanocytes. These results indicate that
SCAM tumor are not of melanocyte origin (Fig.22). The experiment was repeated in
tumors isolated from the back, ear, eye and tail of 4 mice and similar results were
obtained
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Fig.21 Non pigmented tumor in SCAM mouse
Cutaneous Tumor in SCAM mouse indicated by an arrow. The SCAM mice are on k14SCF background thus showing pigmented skin, but upon excision the tumor was not
pigmented.
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Fig.22 FACS analysis of SCAM tumor cells for presence of melanoma markers
FACS analysis of SCAM tumor cells stained with cocktail of antibodies against TRP-1,
tyrosinase, HMB45, gp100 and MART-1. Mouse melanocyte cultures were used as
positive control. Grey peak represent isotype control, while the red peak represent
antibody staining.
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b) Melanoma markers analysis by immunohistochemistry
SCAM tumor cells plated in chamber slides and stained for the presence of gp100
(HMB45; blue) and TRP-1(red). While B16 melanoma cells express both gp100 and
TRP-1 seen as purple stain, SCAM tumor cells lacked the expression of either gp100 or
TRP-1 (Fig.23), further confirming that the tumors are not melanomas.
c) PCR analysis of melanoma markers at RNA level
RNA isolated from SCAM tumor and mouse melanocytes was reverse transcribed
and amplified using specific mouse primers to full-length TRP-2 and gp100.

No

amplification was observed in the cDNA derived from the RNA of SCAM tumor cells,
while the targets were successfully amplified from the positive controls (Fig.24).
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Fig.23 Immunohistochemistry of SCAM tumor cell
SCAM tumor cells stained for gp100 (blue) and TRP-1(red) expression. B16F10 mouse
melanoma cells served as a positive control and MOVAS cells (mouse smooth muscle
cells) served as a negative control.
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Fig. 24 Amplification of melanoma markers in SCAM tumor cells
Primers were designed to amplify full length TRP-2 and gp100 from cDNA obtained
from SCAM tumor cells and mouse melanocytes. Mouse melanocytes served as positive
controls. Expected product sizes are 1611 and 1878 for TRP-2 and gp100 respectively as
boxed in the Fig.24.
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d) Identification of melanoma markers by Western blotting
Proteins isolated from two SCAM tumors (tail and back), B16 melanoma cells and wild
type mouse kidney cells were separated in SDS-PAGE gel and probed with antibodies to
TRP-1 (Red). SCAM tumor cells did not demonstrate expression of TRP-1, while the
mouse melanoma cells did express TRP-1 (Fig.25)
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a

Fig.25 Identification of melanoma markers in SCAM tumor cells by Western
blotting
Proteins isolated from SCAM tumor cells, B16F10 mouse melanoma cells (positive
control) and wild type mouse kidney cells (negative control) were separated and stained
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for TRP-1 (red). Expected band size for TRP-1 is 70KD. TRP-1 staining in the positive
control indicated by a red box. Mouse kidney cells show anon-specific band from
staining with an irrelevant antibody to S100 in the same blot in blue. Fig 25a represent
the whole blot and 25b represent lanes of intrest.
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Generation of black (non-agouti) SCAM mice
The Ink4a/Arf -/- Y Tyr RAS transgenic mice were originally generated in albino
mice on an agouti background. Since the F1 offsprings from Ink4a/Arf-/- Y Tyr Ras mice
and k14-SCF Tg mice were backcrossed with Ink4a/Arf -/- Y Tyr RAS Tg mice, the
offsping were all agouti in trait. The agouti signaling protein acts on melanocortin
receptors thereby reducing tyrosinase activity and melanogenesis(210). Since the
tyrosinase promoter in SCAM mice should drive oncogenic RAS, we hypothesized that
the agouti signaling protein can act as a negative switch for the expression of oncogenic
RAS, leading to formation of non-melanoma tumors. Therefore, the agouti trait was
eliminated by selecting only the black offspring among F2 mice. Black mice with skin
pigmentation along with loss of Ink4a/ARF were selected for future breeding. Male mice
were maintained until cutaneous tumors developed. Resulting tumors were nonpigmented and did not express any melanoma markers suggesting that presence of agouti
was not responsible for the lack of expression of RAS from the tyrosinase promoter
(Fig.26).
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Fig.26 Generation of black SCAM mice
Non-agouti pigmented male mouse displaying a non-pigmented tumor growing through
the skin represented by a black arrow.
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Characterization of Ink4a/ARF -/- Y Tyr Ras transgenic mice
Cutaneous tumors from parental male Ink4a/Arf -/-Y Tyr HRAS transgenic mice
were characterized to confirm melanoma development in parental males.
a)Melanoma markers analysis by immunohistochemistry
Immunohistochemical analysis of cultured tumor cells from Ink4a/Arf male mice
using antibody HMB45 to gp100 and Ta99 antibody to TRP-1 did not show any staining
suggesting that the tumor cells are non melanomas (Fig.27a). Similar results were
obtained upon staining of cryosections obtained from tumor tissues from Y Tyr H RAS
Ink4a/Arf-/- male mice with anti-TRP-1 antibody. Staining of a normal eye of SCAM
mice served as positive control. (Fig.27b).
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Fig.27 Immunohistochemical analysis of Ink4a/ARF tumor
a)Tumor cells obtained from Ink4a/Arf-/- male mice were stained for the presence of
gp100 (blue) and TRP-1 (red). B16F10 melanoma cells served as a positive control and
MOVAS cells served as a negative control.

b) Tumor sections from male albino

Ink4a/Arf-/- Tyr Ras mice stained to detect TRP-1 protein using immunohistochemistry.
Normal eye tissue of a SCAM mouse is used as positive control. Hematoxylin was used
as a counter stain.
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b) Identification of melanoma markers by Western blotting.
Tumor cells obtained from male Ink4a/Arf -/- Y Tyr Ras transgenic mice were
separated in an SDS-polyacrylamide gel and stained for the presence of TRP-1 protein
(red). Similar to the immunohistochemical analysis, the tumor cells lacked the presence
of TRP-1 staining, however the B16F10 melanoma cells showed the expressionof TRP-1
(red) with a correct molecular weight of 70KD (Fig.28).
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a

Fig 28 Western blot of Ink4a/Arf-/- male mice tumor
Proteins from B16F10 melanoma cells (positive control), kidney cells from a wild type
mouse (negative control) and Y Tyr HRAS Ink4a/Arf-/- male tumor cells stained for the
presence of TRP-1 (70KD-red). Boxed band represent proteins of correct size. This
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western blot was performed as part of the experiment shown in Fig.23 and the same
control lanes were shared between both experiments. As mentioned previously, blue
bands represent non-specific staining in control kidney cell and Y Tyr HRAS Ink4a/Arf/- male mouse tumor cells in blue.
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c) Presence of RAS gene under tyrosinase promoter
To identify whether RAS is expressed under the tyrosinase promoter in
Ink4a/Arf-/- Y Tyr RAS mice, attempts were made to amplify the transgenic Tyr-RAS
construct. The upstream primer was designed for tyrosinase promoter as supposedly
included in the original construct, combined with downstream primers to specifically
amplify human Harvey RAS and not endogenous mouse RAS. Lack of any amplification
using the Tyr-Ras primer set suggested that tyrosinase promoter may not drive RAS
expression. However, human Harvey RAS was successfully amplified from male Y Tyr
H RAS Ink4a/ARF-/- Tg mice and not in female mice, supporting that human HRAS
DNA is integrated into the Y chromosome (Fig.29). Taken together with the absence of
melanoma associated markers from resulting tumors, it is likely that the parental
Ink4a/Arf-/- Ras Tg model does not carry the parental genopype and phenotype and is
therefore not a useful melanoma model.
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Fig. 29 Identification of RAS upstream of tyrosinase promoter in Ink4a/Arf mice
A) Primers designed to amplify the tyrosinase promoter reading in to the human HRAS
gene in male mice. DNA from Ink4a/Arf-/- mice is shown for the absence of RAS and
the Ink4a/Arf genes, in presence of the neomycin insert. TR1, TR2 and TR3 represent
different forward primers for the mouse tyrosinase promoter combined with reverse
primers for human RAS gene. T represents amplification of the tyrosinase promoter. R
represents the human HRAS gene. G stands for GAPDH. Boxed bands represents
products of the correct, expected size bands, unboxed bands are non-specific bands.
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Determination of anti tumor immune responses mediated by MBEH
Anti-tumor immune responses mediated by MBEH were measured by challenging
MBEH pre-treated or vehicle treated k14-SCF mice with B16 melanoma cells and
comparing tumor progression. In addition, immune infiltration of the remaining tumor
tissues was studied.
a) Cytotoxicity of MBEH to mouse melanoma cells and melanocytes
To identify whether MBEH mediates direct cytotoxicity towards B16F10 mouse
melanoma cells, the viability of cultured B16 melanoma cells and melanocytes (derived
from k14-SCF mice) in response to 250, 500 and 900 µM concentration of MBEH for 24
hours was determined in MTT assays. In Fig.30 data are pooled from two independently
performed experiments. Vehicle treatment served as a control for both cell types. The
viability of mouse melanocytes was reduced by 30%, 48% and 59% upon 250, 500 and
900 µM of MBEH treatment respectively. However, no significant reductions was
observed in the viability of B16F10 melanoma cells even at the highest concentration of
MBEH. This confirms that mouse melanocytes were sensitive to bleaching agents MBEH
as previously shown for human melanocytes (chapter 3), whereas melanoma cells are
highly resistant to the same chemicals.
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Fig.30 Cytotoxicity of bleaching agent MBEH towards B16 melanoma cells and
mouse melanocytes
Sensitivity of B16F10 melanoma cells and k14-SCf derived melanocytes upon treatment
with MBEH. Data from 2 independent experiments were combined with triplicate values
for each experiment. Mean and SE were calculated and statistical significance was
evaluated by Student’s t- test by comparing the viability of cells upon vehicle and MBEH
treatment. ‘***’ indicates p<0.0001.
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b) Tumor challenge of k14- SCF mice with B-16 melanoma cells
Tumor volume was measured in MBEH or vehicle pretreated k14-SCF mice upon
challenging with B16F10 melanoma cells. Data from two independent experiments were
combined as shown in Fig.31. Greater than 70% reduction in tumor growth in MBEH
treated mice in comparison with vehicle treatment was observed at days 11,12,13 and 14
post challenge (p<0.05).. At day 14 an average tumor volume of 511mm3 was measured
for vehicle treated mice whereas MBEH treated mice displayed an average tumor volume
of 82 mm3 (p<0.05). Mice were euthanized at day 14.
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Fig.31 Tumor challenge of k14-SCF mice with B16 melanoma cells
Treatment of k14-SCF mice with 1.5M of MBEH or vehicle alone for 3 weeks preceded
a tumor challenge with B16F10 melanoma cells subcutaneously in the flank region. The
volume of the tumor was measured daily from day-10 onwards. Closed circles represent
vehicle treated (control) mice, and open triangles represent the MBEH treated group.
Data were pooled from two independent experiments for a total of 8 vehicle treated and
10 MBEH treated animals. Statistical significance of differences among treatment groups
was evaluated using Student’s t- test ‘*’ indicates p<0.05
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c) Cytokine profiling of the tumors
The type of anti-tumor immune response activated by MBEH was identified by
quantifying the expression levels of pro and anti-inflammatory cytokines in remaining
tumor tissue using qRTPCR. In parallel with the cytokine environment observed in
C57BL/6 mice skin after treatment with MBEH (chapter 3), increased expression levels
of TNF α, IFN-γ, IL-2, IL-12 were observed with a relative increase of 5.1, 3.7, 3.4, 7.1
fold over vehicle treatment, respectively. Interestingly, in addition to a Th1 environment,
substantial levels of IL-17 were observed with a 7.6 fold increase over vehicle treatment.
Expression levels of IL-4 and IL-10 were also increased 2.8 and 1.9 fold over vehicle
treatment respectively, and overall these data suggest a Th1/Th17 cellmediated and
inflammatory immune response corresponding to

increased anti tumor reactivity in

tumor from MBEH pre-treated mice (Fig.32a). In Fig.32b, relative fold change over
vehicle for pro and anti-inflammatory cytokines was quantified by normalizing to CD3
expression levels. A comparison between Fig. 32a and 32b demonstrates that elevated
cytokine expression in tumors from MBEH pretreated mice is due in part to enhanced
infiltration by T cells, warranting a further comparison of effector T cell infiltration in
either group, as shown in Fig.32.
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Fig32 Cytokine profiling in the tumor environment
a) Transcript levels of pro and anti-inflammatory cytokines evaluated by qRT-PCR in
mouse tumor samples. Levels were expressed as transcript abundance for the cytokine
per GAPDH transcript content. The relative fold change in the transcript levels following
MBEH treatment is shown upon normalization to vehicle treatment. Mean and standard

143
deviation were calculated from 3 replicates. Experiments were repeated thrice and data
from a representative experiment are shown. b) The relative fold change in the expression
level of pro and anti-inflammatory cytokines was quantified over vehicle treatment after
normalization with CD3 transcript levels.
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d) Infiltration of cytotoxic T cells in the tumor tissue
The consequence of a Th1 cytokine environment was further established in the
remaining tumor tissue by quantifying the abundance of cytotoxic CD8+T cells in either
group. Representative stainings are shown for 3 mice from either group (Fig.33). CD8+T
cell infiltration was 4.7 fold increased in remaining tumor tissue from 3 animals
compared to tumors resected from 3 vehicle treated animals, which was significant at
p<0.01 in Student's t-test. These data suggest that anti-tumor protection provided by
MBEH pre-treatment may be attributed at least in part to cytotoxic T cells activity.

145

Fig.33 Infiltration of CD8+ T cells in the remaining tumor
Infiltration by CD8+ T cells was quantified in remaining day 14 tumor tissue from k14SCF mice pre treated with vehicle or 1.5M MBEH for 3 weeks. Representative
microscopic fields are shown above with its quantification in the below panel in Fig. 33.
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Discussion
Mice are the most commonly used species to generate melanoma models among
vertebrates, as they can be genetically manipulated with relative ease. It should be kept in
mind that even when desired phenotype is obtained for a particular mouse model, desired
genetic alterations may not be indefinitely stable.
The data presented here demonstrate that our SCAM mice did generate cutaneous
tumors, however the tumors lacked expression of melanoma markers, despite the mice
being null for the Ink4a/Arf genes, along with the presence of human RAS gene
specifically in males. FACS analysis, western blot and immunohistochemical studies of
SCAM tumor tissues and cells clearly showed the protein level expression of melanoma
markers such as tyrosinase, TRP-1,

gp100 or MART-1 were absent. Absence of

melanoma markers at the transcript level further validated that the tumor cells were not of
melanoma origin.
The agouti signaling protein acts as an inverse agonist for α-MSH thereby
affecting the activity of tyrosinase gene (211). Since the SCAM mice were initially
generated on an agouti background, it was thus hypothesized that presence of agouti trait
reduced the activity of the tyrosinase promoter, thereby inhibiting oncogenic RAS
expression. However, lack of pigmented melanoma in the SCAM mice generated on a
black background suggested that the tyrosinase promoter may not be driving oncogenic
RAS expression. It was shown that activity of oncogenic RAS is critical for the
penetrance and maintenance of melanoma in the Ink4a/Arf knockout mouse model (212).
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Identification of human Harvey RAS encoding DNA only in the male SCAM mice and
not in female animals confirms that the human RAS gene is integrated in the Y
chromosome; however, its expression is not likely driven by the tyrosinase promoter.
Taken together with the absence of melanoma associated markers from resulting
tumors, it is unlikely that the parental Tyr H-RAS Ink4a/Arf-/- mouse model is an
appropriate melanoma model to study treatment efficacy for any given melanoma
treatment, including the tumor preventive effects of topical bleaching agent MBEH..
In previous chapters, it was shown that MBEH induces necrotic melanocyte death
(chapter 2). Further, in vivo studies, demonstrated that application of MBEH to mouse
skin activated a predominantly Th1 mediated immune response (chapter 3). Therefore, it
is possible that necrotic death of melanocytes in pretreated skin will trigger an immune
response that is powerful enough to keep subsequent tumors in check. This concept was
subsequently tested in a tumor challenge model where depigmenting k14-SCF mice upon
MBEH treatment was challenged with B16 melanoma cells. The resistance of mouse
melanoma cells to MBEH mediated toxicity renders the circumstances unlikely for a
direct (biochemical) effect on B16F10 melanoma cells. Significantly, reduced tumor
growth upon MBEH pretreatment confirmed an anti-tumor immune response activated by
MBEH pre-treatment.
Elevated levels of Th1 and Th17 cytokines in the remaining tumor suggest that
the MBEH driven anti-tumor response is mediated, at least in part, by cytotoxic T cells,
supported by an inflammatory environment. Finally, marked infiltration of CD8+ T cells
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support the concept that significant inhibition of tumor growth upon MBEH pretreatment
was primarily due in part to CTL activity.
It has been reported that elimination of melanocytes by MBEH is permanent (184).
For melanocytes that are not eliminated by MBEH treatment or due to the immune
response that follows, it may be important to drive recall responses in patients where
remaining melanocytes malignantly transform at a later time point. This question was
addressed by van den Boorn et al in a recent publication where MBEH treatment was
combined with adjuvants imiquimod and CpG (153). Anti-tumor reactivity was observed
even 165 days after cessation of the treatment, thus supporting lasting effects of MBEH.
In conclusion, in vivo data provide for the concept that topical application of bleaching
phenols can serve as a prophylactic agent to support the prevention of tumor growth in
familial melanoma patients and patients concerned about tumor recurrences. Such
protection is offered in a 2-tiered approach, by eliminating precursor cells of the
melanocyte lineage that can otherwise malignantly transform, and by eliciting an immune
response to melanoma associated antigens. Such response is required to support the
removal of distant melanocytes from sites not exposed to MBEH, as well as to otherwise
insensitive melanoma cells that share expression of melanocyte differentiation antigens
and may be targeted by an effective immune response to the same. In particular, gp100
and MART-1 and tyrosinase are among the most immunogenic molecules expressed by
melanoma cells (115, 213-214). Taken together, the data offer pre-clinical support for the
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establishment of topical depigmentation as a potent prophylactic treatment against
melanoma.

CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
Melanoma is the most aggressive skin tumor. The most effective way to reduce
the morbidity and mortality associated with cutaneous melanoma is by identifying the
tumor at an early stage when surgical removal of the tumor is still a curative option (49).
Although the design of therapeutic drugs to target melanoma is an active field of research,
avoiding excessive sunlight remains the only preventive approach for melanoma, in
particular for people with a genetic predisposition to tumor development (48).
Inducing a vitiligo-like condition can serve as a preventive treatment for familial
melanoma since a striking dichotomy exists between vitiligo and melanoma. T cells
recognizing melanosomal antigens were reported both in vitiligo and melanoma
conditions, thus suggesting an immune mediated response in the disease pathogenesis
(145) . An approach derived from this observation include the cloning of high affinity T
cell receptors from T cells infiltrating vitiligo skin which may be introduced into
lymphocytes from melanoma patients to redirect the anti-tumor response (150). This
approach is not yet in clinical stage and is experimentally challenging.
In vitiligo patients, depigmentation of the skin progresses with a pace of, on
average, 1% of the skin surface per year (146). Depigmentation is also observed in
patients with malignant melanoma that develop a significant adaptive immune response
to the tumor
150
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(215). Although depigmentation is generally not desirable for vitiligo patients, once the
disease has advanced beyond approximately 50%, patients can opt for chemical
depigmentation to achieve an even skin tone (216). Meanwhile, such depigmentation
after vaccine therapy is considered as a positive prognostic factor in case of melanoma
patients (217).
Bleaching phenolic compounds 4-TBP and MBEH were reported to induce
vitiligo-like depigmentation for patients working in rubber, tannery industries (155, 218) .
Therefore, we exploited whether these bleaching agents could be used in designing
preventive therapy for melanoma.
In order to design a preventive strategy, the bleaching agents should specifically
remove melanocytes and well as activate an immune response to target melanocytes at
farther sites. Since 4-TBP was already known to induce apoptotic destruction of
melanocytes, we wanted to understand whether MBEH is toxic to melanocytes.The data
presented here demonstrate that MBEH, similar to, 4-TBP, induces specific melanocyte
death when compared to keratinocytes. However, the cytotoxic effects were similar in
fibroblasts and melanocytes. These data support the notion that topical application will
selectively eliminate melanocytes among epidermal cells, at the same time suggesting
that systemic application of either agent is associated with toxicity towards cells other
than melanocytes. Interestingly, the mode of melanocyte death mediated by MBEH was
identified as necrotic and not apoptotic death as induced by 4-TBP. In addition, 4-TBP
and MBEH had a differential response in the pigmentary system, where presence of
melanin protected against the toxicity mediated by MBEH and not 4-TBP. MBEH and
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not 4-TBP was also shown to upregulate the expression levels of melanogenic enzymes.
This suggest that a balance exist between the protective effects mediated by melanin and
toxic effects of generated orthoquinones and melanocyte death occurs which ever
predominates. This protective effect of melanin upon MBEH mediated cytotoxicity could
however be problematic to vitiligo patients as people with a darker skin tone would have
relatively less effect upon MBEH mediated depigmentation, however could be beneficial
for melanoma patients as people with lighter skin tone offer presents with a greater risk
of melanoma. Finally, MBEH but not 4-TBP generates ROS in melanocytes. As it was
recently shown that expression of p16Ink4a is required for metabolizing ROS, it is clear
that cells lacking expression of this oncogene will be increasingly sensitive to MBEH
treatment (219).
Given the different modes of cell death induced by either agent, it is reasonable to
assume that the extent of an immune response that follows exposure to 4-TBP or MBEH
will differ, (220) . Indeed, it was shown that only MBEH and not 4-TBP does activate a
potent immune response by causing emigration of Langerhans cells from the human
epidermis and infiltration of T cells and macrophages in mice skin supported by an
increased Th1 mediated cytokine environment upon topical treatment.
The bleaching phenols like 4-hydroxyanisole and 4s-CAP have been used in the
melanoma treatment. However, much progress could not be made by using phenolic
bleaching agents as a single agent to treat melanoma because melanoma cells
relatively resistant to these agents. The data presented in chapter 3 shows clearly that

are
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human melanoma cells such as 888, 624.38, A375 and M14 are significantly resistant to
both 4-TBP and MBEH in comparison with melanocytes. In contrary, a recent work by
van den Broon demonstrates that MBEH sensitizes melanoma cell lines such as mel AKR,
mel 136.2 (221). This again emphasizes the necessity of using these chemicals in
preventive approach as differential sensitivity is being demonstrated by melanoma cells.
Differential sensitivity among normal and tumor cells may be defined by multi-drug
resistance transporters that pump the chemicals back out of malignant cells, and phenolic
agents may never reach the melanosomal compartment to react with melanosomal
antigens (222). Alternatively, a different composition of the melanosomal compartment
with progressive loss of melanosomal enzymes may determine their relative insensitivity
(223-224). Studies to unravel intracellular trafficking are important to help lift the veil
surrounding this topic, and potentially expand the use of phenolic bleaching agents to a
therapeutic setting in the future. This is one of several items to be addressed in order to
further optimize the promising anti-tumor treatment presented here. Further items are
addressed in the paragraphs below.
The process of cellular uptake and whether MBEH and/or 4-TBP are trafficked to
melanosomes or elsewhere within the cells can be understood by labeling the bleaching
compounds and following the intracellular trafficking in melanoma and melanocytes. The
observation that 4-TBP and MBEH binds tyrosinase suggests that at least part of the
compounds are trafficked through the melanosome (116, 118).
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The trafficking of bleaching compounds into the melanosomes of the melanoma
cells can be improved using a “Trojan Horse-like” concept, where phenolic compounds
can be packed in microbeads such as chitosan. Chitosan is the alkaline deacetylated
product of chitin, which is derived from the exoskeleton of crustaceans (225) . Chitosan
is widely used in the biological drug delivery system. Melanocytes are capable of
phagocytosis using melanosomes which would perform the function of lysosomes to
complete endosomal fusion (226). This phagocytic potential of melanocytes may be
exploited to deliver the bleaching compounds into the melanoma cells. However, it is
also possible that the ultimate destination of bleaching compounds lies outside the
melanosome, in which case charged nanoparticles could instead be used to target these
compounds in to the melanoma cells(138).
In order for a lasting bleaching effect to protect against future tumor occurrences,
it is important that the bleaching compounds also eradicate undifferentiated melanocyte
stem cells. Occasional repigmentation in vitiligo patients upon MBEH treatment suggests
that melanocyte stem cells are insensitive to MBEH. In recent studies performed by the
Johnson lab, compounds that are capable of preventing melanocyte differentiation in
zebrafish have been identified (227). A 1280-compound screening identified novel agents,
affecting melanocyte differentiation and viability. The identification of 8-DPAT suggests
that treatment with this agent is capable of eliminating cells determined to become
melanocytes but not yet sensitive to compounds affecting melanogenesis. Also,
compounds papaverine and isoliquiritigenin affect c-kit induced migration of melanocyte
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stem cells. These compounds can be tested either solely or synergistically with MBEH in
mice and in human explant cultures to identify their impact on melanocyte physiology.
The depigmenting effects of MBEH are well established in vitiligo patients,
however, it was not known whether similar depigmentation effects could be achieved
targeting melanocytes in control individuals, since it is generally believed that vitiligo
melanocytes are specifically vulnerable and increasingly sensitive to external stress
compared to healthy melanocytes. The depigmentation studies performed in wild type
C57BL/6 mice and k14-SCF mice clearly showed that MBEH can induce significant
depigmentation in healthy melanocytes and not just in vitiligo patients. Preliminary
studies conducted in the lab to identify the relative sensitivity of normal and vitiligo
melanocytes upon treatment with MBEH or 4-TBP indeed showed no intrinsic
differences in sensitivity (data not shown). However, it is possible that true differences
can be observed only under limiting culture conditions or that further ex vivo or in vivo
studies are most suited to understand the intrinsic differences in their sensitivity levels.
This can be done using vitiligo mouse models, that develop spontaneous vitiligo due to
the expression of a transgenic T cell receptor reactive with mouse tyrosinase (228).
It will be of interest to explore whether melanocytic nevi cells are sensitive to
MBEH application. Patients predisposed to melanoma development have a tendency to
express greater than 50 nevi at any time (48). Since these nevi carry the primary burden
of transformation risk, depigmentation induced nevus removal may be a direct method to
remove benign precursor lesions while inducing a more prominent immune response. As
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we have shown that melanin offers a level of protection towards toxicity mediated by
MBEH (chapter 2), the immune effects may require further boosting using adjuvant
therapy such as CpG and imiquimod that was shown to offer therapeutic anti-tumor
reactivity for extended periods of time (153). Since topical application of imiquimod
have shown to target the Lentigo melanocytes, combination of MBEH and imiquimod
might activate a suitable environment as MBEH targets the melanocytes and
immiquimod boost the TLR 9 mediated immune response(229)
Taken together, the data offer pre-clinical support for the establishment of topical
depigmentation as a prophylactic treatment against melanoma. MBEH may therefore be
of direct use for patients with FAMMM (familial atypical multiple mole melanoma
syndrome). To test, its prophylactic potential, further evaluation can be performed in
pigmented mouse melanoma model. Failure of the mouse tyrosinase promoter to drive
the human RAS expression might have resulted in the generation of unpigmented
cutaneous tumors. A new-pigmented melanoma mouse model may be generated by
crossing mice with oncogenic human N RAS driven by mouse tyrosinase promoter on an
Ink4a/Arf null background to k14-SCF tg mice. This model include will better represent
human melanomas, as individuals with melanoma frequently have N RAS mutations
instead of H RAS. In addition, spontaneous melanomas generated in Tyr N RAS
Ink4a/Arf-/- mice with pigmented skin are expectedly metastatic in nature.
In conclusion, our data support that the greatest potential of bleaching
phenols in anti-tumor treatment revolves around prophylactic applications.
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